<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006931" GROUP_ID="EYES" ID="546306112410145060" MERGED_FROM="" MODIFIED="2009-02-18 20:22:59 +0100" MODIFIED_BY="Anupa Shah" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2009-02-18 20:22:59 +0100" MODIFIED_BY="Anupa Shah">
<TITLE>Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration</TITLE>
<CONTACT MODIFIED="2009-02-18 20:22:59 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="193D1E4682E26AA201BA4B5433A0FDB9" ROLE="AUTHOR"><FIRST_NAME>Fabrizio</FIRST_NAME><LAST_NAME>Giansanti</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>fabrizio.giansanti@unifi.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neuro-Oto-Ophthalmological Surgical Sciences, Eye Clinic</DEPARTMENT><ORGANISATION>University of Florence</ORGANISATION><ADDRESS_1>Via le Morgagni 85</ADDRESS_1><CITY>Florence</CITY><ZIP>50134</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 055 411765</PHONE_1><FAX_1>+39 055 4377749</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-02-18 20:22:59 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="193D1E4682E26AA201BA4B5433A0FDB9" ROLE="AUTHOR"><FIRST_NAME>Fabrizio</FIRST_NAME><LAST_NAME>Giansanti</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>fabrizio.giansanti@unifi.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neuro-Oto-Ophthalmological Surgical Sciences, Eye Clinic</DEPARTMENT><ORGANISATION>University of Florence</ORGANISATION><ADDRESS_1>Via le Morgagni 85</ADDRESS_1><CITY>Florence</CITY><ZIP>50134</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 055 411765</PHONE_1><FAX_1>+39 055 4377749</FAX_1></ADDRESS></PERSON><PERSON ID="100FDA6C82E26AA20003EB8A782C55B6" ROLE="AUTHOR"><FIRST_NAME>Chiara</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Eandi</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>chiara.eandi@unito.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Physiopathology, Eye Clinic</DEPARTMENT><ORGANISATION>University of Torino</ORGANISATION><ADDRESS_1>Via Juvarra 19</ADDRESS_1><CITY>Torino</CITY><ZIP>10122</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 011 5666032</PHONE_1><FAX_1>+39 011 539024</FAX_1></ADDRESS></PERSON><PERSON ID="11340" ROLE="AUTHOR"><FIRST_NAME>Gianni</FIRST_NAME><LAST_NAME>Virgili</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Associate Professor of Ophthalmology</POSITION><EMAIL_1>gianni.virgili@unifi.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neuro-Oto-Ophthalmological Surgical Sciences, Eye Clinic</DEPARTMENT><ORGANISATION>University of Florence</ORGANISATION><ADDRESS_1>Via le Morgagni 85</ADDRESS_1><CITY>Florence</CITY><ZIP>50134</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 055 411765</PHONE_1><FAX_1>+39 055 4377749</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-02-13 13:33:01 +0000" MODIFIED_BY=" Iris Gordon">
<UP_TO_DATE>
<DATE DAY="11" MONTH="2" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="2" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="1" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-12-15 16:37:09 +0000" MODIFIED_BY="Anupa Shah"/>
<HISTORY MODIFIED="2009-02-18 17:35:35 +0000" MODIFIED_BY="Anupa Shah">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-12-15 16:37:09 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="12" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-12-15 16:36:22 +0000" MODIFIED_BY="Anupa Shah">
<INTERNAL_SOURCES MODIFIED="2008-12-15 16:36:22 +0000" MODIFIED_BY="Anupa Shah">
<SOURCE MODIFIED="2008-12-15 16:36:22 +0000" MODIFIED_BY="Anupa Shah">
<NAME>University of Florence</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-02-18 19:21:23 +0000" MODIFIED_BY="Anupa Shah">
<SUMMARY MODIFIED="2009-02-18 17:40:36 +0000" MODIFIED_BY="Anupa Shah">
<TITLE MODIFIED="2008-12-12 17:27:00 +0000" MODIFIED_BY="Gianni Virgili" NOTES="&lt;p&gt;I am not sure the last sentence makes sense.&lt;/p&gt;" NOTES_MODIFIED="2008-12-12 17:27:00 +0000" NOTES_MODIFIED_BY="Gianni Virgili">Surgical removal of choroidal neovascularisation in patients with neovascular age-related macular degeneration</TITLE>
<SUMMARY_BODY MODIFIED="2009-02-18 17:40:36 +0000" MODIFIED_BY="Anupa Shah">
<P>Neovascular or wet age-related macular degeneration (AMD) is caused by blood vessels growing as a layer of tissue under the central retina (the macula). The disease leads to the development of a blind spot in the centre of the visual field and is the most common cause of legal blindness among the elderly in the western world. Surgery has been used to remove tissue lying beneath the macula, within which grow the small, new blood vessels which are the cause of wet AMD. It was hoped that removal of this tissue might limit the development of AMD, and perhaps even improve vision. </P>
<P>We found two large multicentre studies conducted in 790 people affected by choroidal neovascularisation, with or without extensive blood beneath the macula. The results of these studies suggested that visual loss cannot be prevented using surgery. In addition, complications such as cataract and retinal detachment can arise during follow-up, in patients who have the procedure.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-02-18 17:37:02 +0000" MODIFIED_BY="Anupa Shah">
<ABS_BACKGROUND MODIFIED="2009-02-18 17:36:02 +0000" MODIFIED_BY="Anupa Shah">
<P>Vitreoretinal surgeons proposed submacular surgery to remove the fibrovascular tissue causing damage to the centre of the retina, in the attempt to limit central visual loss in people affected by neovascular age-related macular degeneration (AMD).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-11-30 09:48:28 +0000" MODIFIED_BY="Gianni Virgili">
<P>This review aims at assessing the effectiveness of submacular surgery for preserving or improving vision in patients with AMD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-02-13 13:33:33 +0000" MODIFIED_BY=" Iris Gordon">
<P>We searched CENTRAL, MEDLINE, EMBASE and LILACS. There were no language or date restrictions in the search for trials. The electronic databases were last searched on 11 February 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-12-15 16:38:51 +0000" MODIFIED_BY="Anupa Shah">
<P>We included randomised or quasi-randomised controlled trials comparing submacular surgery with any other treatment or observation.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-12-12 17:14:27 +0000" MODIFIED_BY="Gianni Virgili">
<P>Two authors independently extracted the data. The risk ratio (RR) of visual loss and visual gain was estimated at one year.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-02-18 17:37:02 +0000" MODIFIED_BY="Anupa Shah">
<P>Two multicentre studies with a similar design were conducted between 1997 and 2003 and compared submacular surgery with observation in people affected by subfoveal neovascular AMD with (n=336) or without (n=454) extensive blood in the macula. At one year there was high quality evidence of no benefit for preventing visual loss (RR: 0.96; 95% confidence interval (CI): 0.84 to 1.09). No difference could be demonstrated regarding the chance of visual gain (RR: 1.06; 95% CI: 0.75 to 1.51), although this evidence was of low quality because of imprecision. The risk difference was -2% (95% CI: -10% to 5%) and 1% (95% CI: -4% to 6%) for visual loss and visual gain, respectively, thus excluding a large benefit with surgery in terms of absolute risk in this sample. There was high quality evidence that cataract needing surgery (RR: 8.69; 95% CI: 4.06 to 18.61) and retinal detachment (RR: 6.13; 95% CI: 2.81 to 13.38) were more common among operated patients, and detachment occurred in 5% of patients with no extensive blood and in 18% of those with extensive blood beneath the macula.</P>
<P>A pilot study compared submacular surgery with laser photocoagulation in 70 patients. No difference between the two treatments could be demonstrated for any outcome measure, but estimates were very imprecise because of small sample size.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-12-06 16:46:26 +0000" MODIFIED_BY="Gianni Virgili">
<P>There is no benefit with submacular surgery in most people with subfoveal choroidal neovascularisation due to AMD in terms of prevention of visual loss. Furthermore, the risk of developing cataract and retinal detachment increases after surgery.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-02-18 19:21:23 +0000" MODIFIED_BY="Anupa Shah">
<BACKGROUND MODIFIED="2009-02-18 17:56:52 +0000" MODIFIED_BY="Anupa Shah">
<CONDITION MODIFIED="2009-02-18 17:50:50 +0000" MODIFIED_BY="Anupa Shah">
<P>Age-related macular degeneration (AMD) is a progressive and degenerative disease of the retina that occurs with increasing frequency with age. Age-related macular degeneration is the leading cause of legal blindness in people aged 65 years or older. The number of people affected is projected to increase with the continued ageing of the population (<LINK REF="REF-Bunce-2006" TYPE="REFERENCE">Bunce 2006</LINK>; <LINK REF="REF-Friedman-2004" TYPE="REFERENCE">Friedman 2004</LINK>; <LINK REF="REF-Owen-2003" TYPE="REFERENCE">Owen 2003</LINK>). The prevalence of AMD has been estimated to range from 0% among people younger than 55 years to 13% among those aged 80 years or older (<LINK REF="REF-Friedman-2004" TYPE="REFERENCE">Friedman 2004</LINK>). In the Beaver Dam Eye Study, the 10-year incidence of neovascular AMD was 1.4% in those 43 to 86 years of age but increased to 4.1% in people over 75 years of age (<LINK REF="REF-Klein-2002" TYPE="REFERENCE">Klein 2002</LINK>). These findings were slightly lower in the Blue Mountain Eye Study (<LINK REF="REF-Mitchell-1995" TYPE="REFERENCE">Mitchell 1995</LINK>).<BR/>There are two major types of AMD: non-neovascular, or atrophic, and neovascular. The non-neovascular type is characterised by drusen (yellow spots under the retina), pigmentary changes (re-distribution of melanin within the retinal pigment epithelial (RPE) cells under the retina and migration of melanin into the retina), and geographic atrophy (loss of the RPE and choriocapillaris). Neovascular AMD is characterised by the presence of choroidal neovascularisation (CNV). While the non-neovascular type is much more common, it is the neovascular type that is responsible for the most serious loss of vision (<LINK REF="REF-Leibowitz-1980" TYPE="REFERENCE">Leibowitz 1980</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Presentation and diagnosis</HEADING>
<P>Neovascular AMD usually affects one eye at a time. The symptoms of AMD are metamorphopsia (distortions while looking at objects), scotomata (missing spots) and blurry vision. If AMD affects only one eye, visual loss may go undetected until monocular testing at routine eye examinations or by chance occlusion of the better eye.</P>
<P>The diagnosis of AMD can be made clinically and with the help of imaging such as angiography. At the onset of symptoms, fundus examination often reveals subretinal exudation of fluid, lipid, or blood. Fluorescein angiography is necessary to detect subtle exudation in some patients with a recent change in vision. Choroidal neovascularisation has several characteristic patterns on fluorescein angiography. Classic CNV is defined as a well-demarcated area with early hyperfluorescence and increasing fluorescein leakage on late frames of the angiogram. Occult CNV occurs in two different patterns: fibrovascular pigment epithelial detachment (PED) and late leakage of an undetermined source.</P>
<P>Two other imaging tests might be useful to examine patients with neovascular AMD: indocyanine green (ICG) angiography images the choroidal circulation better than fluorescein and may show 'hot' spots under the RPE that are amenable to treatment. Optical coherence tomography (OCT), a non-invasive imaging modality, shows cross-sectional images of the retina, RPE, and choroid. Recent papers define the characteristic appearance of the different stages of the disease process with OCT (<LINK REF="REF-Ting-2002" TYPE="REFERENCE">Ting 2002</LINK>; <LINK REF="REF-Van-Kerckhoven-2001" TYPE="REFERENCE">Van Kerckhoven 2001</LINK>).</P>
<P>The new vessels originating from the choroid and growing under and through the RPE and Bruch's membrane, may leak and bleed causing exudative or haemorrhagic retinal detachments, or both. The process usually evolves into a fibrous scar, which replaces the outer layers of the retina, the RPE and the choriocapillaris. The scarred retina has a greatly diminished visual function.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment options</HEADING>
<P>Treatments for neovascular AMD focus on limiting the growth of new blood vessels within the retina. Original treatments involved application of laser burns to the new vessels (<LINK REF="REF-Virgili-2007" TYPE="REFERENCE">Virgili 2007</LINK>). However concern as to the extent of iatrogenic damage to the retina with such laser treatment led to the development of photodynamic therapy. Photoreactive chemicals are injected into the bloodstream and lower intensity lasers used to activate the chemicals and seal the blood vessels in the retina (<LINK REF="REF-Wormald-2007" TYPE="REFERENCE">Wormald 2007</LINK>). More recent treatments have targeted growth factors within the new vessels. Anti-vascular endothelial growth factors (anti-VEGF) have been shown to be effective in the stabilisation or improvement of visual acuity in people with neovascular AMD and are currently the subject of a Cochrane review (<LINK REF="REF-Krzystolik-2005" TYPE="REFERENCE">Krzystolik 2005</LINK>).<BR/>There are no preventive treatments, however, there is some evidence that antioxidant vitamin and mineral supplementation can slow down the progression of the disease in people with moderate AMD (<LINK REF="REF-Evans-2006" TYPE="REFERENCE">Evans 2006</LINK>).<BR/>Surgical management of neovascular AMD has been studied using different techniques. One approach has been removing the CNV by submacular surgery (<LINK REF="REF-de-Juan-1989" TYPE="REFERENCE">de Juan 1989</LINK>). Other surgical treatments for AMD include pneumatic displacement of submacular blood with or without intravitreal or subretinal injection of recombinant tissue plasminogen activator (<LINK REF="REF-Haupert-2001" TYPE="REFERENCE">Haupert 2001</LINK>; <LINK REF="REF-Herriot-1997" TYPE="REFERENCE">Herriot 1997</LINK>; <LINK REF="REF-Ohji-1998" TYPE="REFERENCE">Ohji 1998</LINK>) and translocation of the macula to an extramacular and healthier RPE area (<LINK REF="REF-Machemer-1993" TYPE="REFERENCE">Machemer 1993</LINK>). A protocol for an overview of interventions for AMD has been published on <I>The Cochrane Library</I> and the review is underway (<LINK REF="REF-Evans-2009" TYPE="REFERENCE">Evans 2009</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2009-02-18 17:52:06 +0000" MODIFIED_BY="Anupa Shah">
<P>In 1989 de Juan et al. reported some cases of submacular scar removal using vitrectomy techniques (<LINK REF="REF-de-Juan-1989" TYPE="REFERENCE">de Juan 1989</LINK>). In 1991 Blinder and colleagues described a technique for excision of submacular scars in AMD and a method of transplantation of the RPE (<LINK REF="REF-Blinder-1991" TYPE="REFERENCE">Blinder 1991</LINK>). These surgeons used a large circumferential retinotomy around the macula to create a flap that is retracted to expose the subretinal space. Subsequently other authors reported variations of this surgical technique (<LINK REF="REF-Berger-1992" TYPE="REFERENCE">Berger 1992</LINK>; <LINK REF="REF-Lambert-1992" TYPE="REFERENCE">Lambert 1992</LINK>; <LINK REF="REF-Thomas-1992" TYPE="REFERENCE">Thomas 1992</LINK>). This procedure involves a standard three-port vitrectomy with or without posterior hyaloid removal, creation of a posterior retinotomy with or without intraocular cautery, optional infusion of subretinal balanced salt solution, mobilisation of the CNV membrane with an angulated pick or other instrument and removal of the membrane with angulated forceps. Intraocular bleeding is controlled by increasing the intraocular pressure, typically by raising the irrigating bottle or using heavy perfluorocarbon liquids. The membrane removal can be augmented with placement of an RPE transplant under the fovea. A partial or complete air-fluid exchange is done and the patient is asked to maintain a prone position until the gas is absorbed.<BR/>Some complications have been reported with submacular surgery (<LINK REF="REF-Lambert-1992" TYPE="REFERENCE">Lambert 1992</LINK>; <LINK REF="STD-SST-2004-Group-B" TYPE="STUDY">SST 2004 Group B</LINK>; <LINK REF="STD-SST-2004-Group-N" TYPE="STUDY">SST 2004 Group N</LINK>; <LINK REF="REF-Thomas-1992" TYPE="REFERENCE">Thomas 1992</LINK>). The most frequent intraoperative complications include haemorrhage under the macula and retinal breaks. The major postoperative complication is retinal detachment. Postoperative recurrence of the subretinal membrane and development of preretinal membrane have been observed.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-02-18 17:55:56 +0000" MODIFIED_BY="Anupa Shah">
<P>The natural course of the disease leads to the formation of a disciform scar and this unfavourable outcome cannot be avoided in all cases with current treatment options. This has led to some surgeons suggesting submacular surgery for those patients not responding to or not eligible for conventional therapies.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-02-18 17:56:52 +0000" MODIFIED_BY="Anupa Shah">
<P>The definitive treatment for neovascular AMD is not established yet. Submacular surgery has been used in different cases. A systematic review of this surgical technique is useful to patients, ophthalmologists and other professionals involved in providing eye health care.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-02-18 17:56:57 +0000" MODIFIED_BY="Anupa Shah">
<P>The objective of this review was to examine the effects of submacular surgery for CNV associated with AMD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-02-18 19:21:23 +0000" MODIFIED_BY="Anupa Shah">
<SELECTION_CRITERIA MODIFIED="2009-02-18 17:57:18 +0000" MODIFIED_BY="Anupa Shah">
<CRIT_STUDIES MODIFIED="2009-02-18 17:57:18 +0000" MODIFIED_BY="Anupa Shah">
<P>We included randomised controlled trials (RCTs) and quasi-RCTs in which the methods of allocating people to a trial are not exactly random such as date of birth, day of the week etc. This is in anticipation of not finding many trials on this subject in future updates of this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-12-12 17:01:14 +0000" MODIFIED_BY="Gianni Virgili">
<P>Participants were people affected by CNV associated with AMD.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-02-12 14:53:46 +0000" MODIFIED_BY="Anupa Shah">
<P>We included any study in which submacular surgery was compared to another treatment, sham treatment or no treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-02-12 14:54:43 +0000" MODIFIED_BY="Anupa Shah">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-12-15 16:58:37 +0000" MODIFIED_BY="Anupa Shah">
<P>The primary outcome for this review was best corrected visual acuity after one year of follow up (plus or minus six months with other time points being secondary outcomes). Visual acuity will be converted to logMAR for calculations if appropriate in updates of this review.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-02-12 14:54:43 +0000" MODIFIED_BY="Anupa Shah">
<P>Contrast sensitivity, reading speed or any other validated measures of visual function as available in the studies.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse outcomes</HEADING>
<UL>
<LI>Any adverse outcomes as reported in trials, particularly retinal detachment.</LI>
<LI>Rate of CNV recurrence.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Economic data</HEADING>
<P>We performed comparative cost analysis if data were available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life data</HEADING>
<P>Quality of life measures were extracted from studies reporting on any validated measurement scale, which aims at measuring the impact of visual function loss on quality of life of participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Outcomes included in the Summary of Findings table</HEADING>
<P>The 'Summary of Findings' table was not available in RevMan when the protocol for this review was written. Therefore, the selection of outcomes to be included in the 'Summary of Findings' table was not prespecified. Since only seven outcomes can be included, we included all outcome measures of the current version of this review.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-02-13 13:57:01 +0000" MODIFIED_BY=" Iris Gordon">
<ELECTRONIC_SEARCHES MODIFIED="2009-02-13 13:57:01 +0000" MODIFIED_BY=" Iris Gordon">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (<I>The Cochrane Library, </I>Issue 1, 2009), MEDLINE (January 1950 to February 2009), EMBASE (January 1980 to February 2009) and Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to February 2009). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 11 February 2009.</P>
<P>See: Appendices for details of search strategies for CENTRAL (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) and LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-02-12 14:56:01 +0000" MODIFIED_BY="Anupa Shah">
<P>We handsearched the reference lists of the included trials for other possible trials. We searched references from the retrieved articles.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-02-18 19:21:23 +0000" MODIFIED_BY="Anupa Shah">
<STUDY_SELECTION MODIFIED="2009-02-18 18:00:51 +0000" MODIFIED_BY="Anupa Shah">
<P>Two review authors independently selected the studies for inclusion. The titles and abstracts of all reports identified by the electronic searches and handsearching were examined by the authors. We classified the abstracts as (a) definitely include, (b) unsure and (c) definitely exclude. We obtained full-text copies of those classified as (a) definitely include and (b) unsure and re-assessed them. We then classified these studies as (1) included, (2) awaiting assessment and (3) excluded. The authors of studies classified as (2) awaiting assessment will be contacted for further clarification and the studies will be re-assessed as further information becomes available in the updates of this review. Studies identified by both review authors as (3) excluded were excluded and reasons for exclusion were documented in the review. Studies identified as (1) included were included and assessed for methodological quality. The review authors were unmasked to the report authors, institutions and trial results during this assessment. Disagreements between the two review authors were resolved by a third review author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-02-18 18:01:21 +0000" MODIFIED_BY="Anupa Shah">
<P>Two review authors independently extracted the data for the primary and secondary outcomes onto paper data extraction forms developed by the Cochrane Eyes and Vision Group. A pilot test of this form was done using a small number of studies. We resolved any discrepancies by discussion. One review author entered all data into RevMan 5. A second review author independently checked the input data for entry errors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-02-18 19:18:06 +0000" MODIFIED_BY="Anupa Shah">
<P>Two review authors independently assessed the included trials for bias according to the methods described in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1</I> (<LINK REF="REF-Higgins-2008a" TYPE="REFERENCE">Higgins 2008a</LINK>). With the update of review management software, we assessed risk of bias using the tool set out in the Handbook.</P>
<OL>
<LI>Sequence generation: the method used to generate the allocation sequence to assess whether it should have produced comparable groups.</LI>
<LI>Allocation concealment: the method used to conceal the allocation sequence to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment.      </LI>
<LI>Masking (blinding) of personnel and outcome assessors: the assessments were made for each main class of outcomes (i.e. anatomic versus functional outcomes). We considered if the methods used (if any) were adequate to mask study personnel from knowledge of participant assignment. Masking of participants was not used since this is a complex surgical procedure and it cannot be simulated.</LI>
<LI>Incomplete outcome data: the assessments were made for each main class of outcomes (i.e. anatomic versus functional outcomes), when possible and were based on the description of the completeness of outcome data, including attrition and exclusions from the analysis and their causes, if they were reported.</LI>
<LI>Selective outcome reporting: the possibility of selective outcome reporting, such as found when some measures were obtained, as declared in the methods section or in protocols, but not reported in the results section.</LI>
</OL>
<P>The following grading was used:</P>
<UL>
<LI>Low risk of bias: plausible bias unlikely to seriously alter the results.</LI>
<LI>Unclear risk of bias: plausible bias that raises some doubt about the results</LI>
<LI>High risk of bias: plausible bias that seriously weakens confidence in the results.</LI>
</UL>
<P>If the information available in the published trial reports was inadequate to assess any of the above items of the risk of bias assessment, we contacted the trial authors for clarification. If they did not respond within a reasonable period of time, we classified the trial based on the available information. When studies did not report any concealment approach, adequacy was considered to be unclear. We also assessed the impact of any assumptions made in this regard in a sensitivity analysis.</P>
<P>We considered a trial to have conducted an intention-to-treat analysis only if it included all participants who were randomised including those randomised but not treated, who were excluded after randomisation for other reasons, and if outcomes were available for all randomised patients.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-02-18 19:18:19 +0000" MODIFIED_BY="Anupa Shah">
<P>Data analysis followed guidelines as in Section 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 </I>(<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). We aimed at calculating a weighted mean difference for continuous outcomes and a standardised mean difference if different scales were used to measure continuous outcomes. However, we did not find this type of data in the included studies, and we could only consider dichotomous data. For dichotomous outcomes we calculated a summary risk ratio. Where possible, we also reported the risk difference and number needed to treat.</P>
<P>Dichotomous visual acuity is commonly reported as a change of 3 or more lines from baseline, which has also been shown to exceed the intersession repeatability of the ETDRS charts (<LINK REF="REF-Patel-2008" TYPE="REFERENCE">Patel 2008</LINK>). However, this cut-off was not available in the included studies, and we used a change of 2 or more lines as the nearest available dichotomisation to calculate risk ratios.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-02-12 15:09:58 +0000" MODIFIED_BY="Anupa Shah">
<P>The unit of analysis was an individual person. If eyes are the unit of randomisation and a relevant proportion of participants (10% or more) have had both eyes randomised we will consider that there is a significant risk of bias in the variance estimate and possibly the point estimate of the outcome measure. Such studies will be excluded in the sensitivity analyses if they are found for future updates of this review.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-02-18 19:21:23 +0000" MODIFIED_BY="Anupa Shah">
<P>Where data are missing due to drop-out of participants in the updates of this review, we will conduct a primary analysis based on patients with complete data (available case analysis) and a sensitivity analysis with missing imputation based on the worst-case/best-case scenarios (<LINK REF="REF-Higgins-2008b" TYPE="REFERENCE">Higgins 2008b</LINK>). This analysis was not possible in the current version of this review because of insufficient reporting of the causes of loss to follow-up, such as when a detailed description is given, including the number of deaths in each arm. If missing imputation is used when updating this review, the assumptions made for imputing will be described. Where statistics such as standard deviations or correlation coefficients are missing, the principal investigators will be contacted for details.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-02-12 15:12:30 +0000" MODIFIED_BY="Anupa Shah">
<P>We looked for clinical heterogeneity by examination of the study details then tested for statistical heterogeneity between trial results using the Chi<SUP>2</SUP> test, and the I<SUP>2</SUP> value (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). We considered I<SUP>2</SUP> values of 30% to 60% to be moderate heterogeneity and values of 50% to 90% to be substantial heterogeneity as recommended by <LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>. We will also examine the funnel plot for other sources of heterogeneity if at least 10 studies are found when updating this review.<BR/>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-12-15 17:07:40 +0000" MODIFIED_BY="Anupa Shah">
<P>Asymmetry of the funnel plot will be used to identify publication bias if at least 10 studies are found when updating this review.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-12-15 17:07:25 +0000" MODIFIED_BY="Anupa Shah">
<P>If more studies are found when updating this review and if there is neither substantial statistical heterogeneity nor clinical heterogeneity between the trials, we will combine the results in a meta-analysis using a random-effects model. A fixed-effect model was used because the number of trials was less than three. In case of substantial statistical or clinical heterogeneity we will not combine study results but present a narrative or tabulated summary if appropriate when updating this review.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-12-16 09:41:11 +0000" MODIFIED_BY="Anupa Shah">
<P>We will conduct subgroup analyses according to type of surgical technique and type of macular lesion to investigate for heterogeneity if appropriate in future updates of this review. We will only conduct subgroup analysis if there is a substantial number of trials in the review (three or more in each subgroup).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-12-15 17:07:15 +0000" MODIFIED_BY="Anupa Shah">
<P>Sensitivity analyses will be conducted to determine the impact of exclusion of studies with lower methodological quality, exclusion of unpublished studies, exclusion of quasi-randomised studies and exclusion of industry-funded studies if further studies are found when updating this review.</P>
<SUBSECTION>
<HEADING LEVEL="5">Methods for future updates </HEADING>
<P>Updates of this review will be conducted every two years after initial publication.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-02-18 19:20:57 +0000" MODIFIED_BY="Anupa Shah">
<STUDY_DESCRIPTION MODIFIED="2009-02-13 14:00:47 +0000" MODIFIED_BY=" Iris Gordon">
<P>The search strategy yielded 66 titles of which 20 were obtained in full and referred to three studies (<LINK REF="STD-SST-2000" TYPE="STUDY">SST 2000</LINK>; <LINK REF="STD-SST-2004-Group-B" TYPE="STUDY">SST 2004 Group B</LINK>; <LINK REF="STD-SST-2004-Group-N" TYPE="STUDY">SST 2004 Group N</LINK>). We found one pilot study comparing submacular surgery and photocoagulation in subfoveal lesions (<LINK REF="STD-SST-2000" TYPE="STUDY">SST 2000</LINK>; 70 patients randomised) and two large studies conducted by the same research group comparing submacular surgery and observation in two different populations with subfoveal lesions: patients with neovascular AMD and no blood (<LINK REF="STD-SST-2004-Group-N" TYPE="STUDY">SST 2004 Group N</LINK>; 454 patients randomised) and patients with blood (<LINK REF="STD-SST-2004-Group-B" TYPE="STUDY">SST 2004 Group B</LINK>; 336 patients randomised). We were also provided with some unpublished data from two pilot SST studies (<LINK REF="STD-SST-Group-B-pilot-trial" TYPE="STUDY">SST Group B pilot trial</LINK>; <LINK REF="STD-SST-Group-N-pilot-trial" TYPE="STUDY">SST Group N pilot trial</LINK>) which are summarised in the '<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>' section. When full data from these pilot SST studies become available they will be included in the updates of this review.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-02-18 19:20:57 +0000" MODIFIED_BY="Anupa Shah">
<P>A summary of risk of bias assessment is shown in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<ALLOCATION MODIFIED="2008-11-11 22:17:07 +0000" MODIFIED_BY="Gianni Virgili">
<P>The allocation sequence in all studies was computer-generated and adequately protected. Thus, the risk of bias was low for these methodological quality items.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-02-18 18:12:48 +0000" MODIFIED_BY="Anupa Shah">
<P>Patients, study personnel and the Photograph Reading Center were not masked in all trials, because this is an invasive surgical procedure and a sham treatment is unlikely to be acceptable (though certainly possible). Moreover, fundus changes related to macular surgery may be recognised by graders of fundus photographs and angiograms. On the other hand, visual acuity examiners were masked, and we suggest that this is sufficient to ensure low risk of bias for functional outcomes. However, lack of patient masking can have serious consequences on quality-of-life data, which is a subjective outcome (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>), even though the interviewers were masked.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-02-18 19:20:57 +0000" MODIFIED_BY="Anupa Shah">
<P>Loss to follow-up was about 10% and was balanced in the study arms of the three included trials. About half of the patients lost to follow-up were due to death within the first two years, and death was not reported to be associated with surgery. Despite the fact that other reasons for loss were not documented in the two arms, except for the overall rate of death, we considered this sufficient to score this item as good quality because the outcomes were not rare. Given that visual loss occurred in about 50% of both observed and treated patients, this scenario is very similar to the example presented in Section 8.12.2.1 "Low risk of bias due to incomplete outcome data&#8221; in the current version of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> 5.0.1(<LINK REF="REF-Higgins-2008a" TYPE="REFERENCE">Higgins 2008a</LINK>). In this example, Higgins et al. estimated an available case RR = 1 as compared to a value of 1.13 obtained including 10% missing cases under heavy assumptions for the impact of 'missingness'.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-02-18 18:15:25 +0000" MODIFIED_BY="Anupa Shah">
<P>For the primary outcome of visual acuity, we extracted dichotomous data for common cut-offs of vision, such as gain or loss of 2 or more lines as a proxy of changes of 3 or more lines, which was not available in the publications. We considered that there was no selective outcome reporting because several cut-offs were presented, and the choice of this dichotomisation was made by us rather than by the study authors. Regarding secondary outcomes contrast threshold and reading speed, one dichotomous outcome measure was obtained from the publications and by study authors. A study protocol was mentioned, but we could not access it to check if these outcomes were pre-specified.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-01-31 21:44:23 +0000" MODIFIED_BY="Gianni Virgili">
<P>We did not identify other sources of bias in the included studies. Furthermore, these studies were mostly funded by public or no-profit institutions.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-02-18 18:35:59 +0000" MODIFIED_BY="Anupa Shah">
<SUBSECTION>
<HEADING LEVEL="5">Macular surgery versus observation</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primay outcome: visual acuity</HEADING>
<P>There was no difference between macular surgery and observation regarding visual loss (risk ratio (RR): 0.96; 95% confidence interval (CI): 0.84 to 1.09) or visual gain (RR: 1.06; 95% CI: 0.75 to 1.51) of 2 or more lines at one year (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The risk difference was -2% (95% CI: -10% to 5%) and 1% (95% CI: -4% to 6%) for visual loss and visual gain, respectively, thus excluding a large benefit with surgery also in terms of absolute risk in these patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes: contrast sensitivity, reading speed</HEADING>
<P>Data on contrast threshold loss of 0.15 log units or more at one year, corresponding to a halving of contrast sensitivity, did not show a statistically significant benefit with surgery (RR: 0.80; 95% CI: 0.63 to 1.02, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>Reading speed at one year was extracted as the proportion of patients reading enlarged text at 40 words/minute or more. No difference between surgery and observation could be demonstrated (RR: 0.88; 95% CI: 0.64 to 1.20, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Quality of life</HEADING>
<P>Quality of life, expressed as loss of 6 or more points of the overall NEI-VFQ questionnaire score, was better for patients assigned to surgery at one year (RR: 1.35; 95% CI: 1.09 to 1.68, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adverse outcomes</HEADING>
<P>The most common adverse outcome was development of cataract needing surgery, which was more common among patients assigned to surgery (RR: 8.69; 95% CI: 4.06 to 18.61, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>A more severe complication was the development of retinal detachment, which was more common among surgery patients (RR: 6.13; 95% CI: 2.81 to 13.38, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) and occurred in 5% of patients in <LINK REF="STD-SST-2004-Group-N" TYPE="STUDY">SST 2004 Group N</LINK> and in 18% of patients in <LINK REF="STD-SST-2004-Group-B" TYPE="STUDY">SST 2004 Group B</LINK>. </P>
<P>We used leakage of dye as a proxy of recurrence of CNV, which was in different directions in <LINK REF="STD-SST-2004-Group-N" TYPE="STUDY">SST 2004 Group N</LINK> (RR: 0.35; 95% CI 0.28 to 0.43) compared to <LINK REF="STD-SST-2004-Group-B" TYPE="STUDY">SST 2004 Group B</LINK> (RR: 1.73; 95% CI: 0.90 to 3.34, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>) and statistically significant in both studies. This may be considered an anatomic outcome measure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Economic data</HEADING>
<P>We found no economic evaluation on macular surgery.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Macular surgery versus laser photocoagulation</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Functional outcomes</HEADING>
<P>For visual acuity, no difference between macular surgery and laser photocoagulation could be demonstrated in this small pilot study (<LINK REF="STD-SST-2000" TYPE="STUDY">SST 2000</LINK>) (see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). We could not extract data on contrast sensitivity and reading speed at one year.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adverse outcomes</HEADING>
<P>Adverse outcomes, specifically cataract surgery and retinal detachment, were more common among patients treated with surgery but few events were recorded and no difference could be demonstrated (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Quality of life data</HEADING>
<P>Using the quality of life questionnaire SF-36, no difference between the two interventions was found for both the physical and the mental subscale (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<P>We did not include this comparison in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> since analyses were based on only one small pilot study.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-02-18 18:48:54 +0000" MODIFIED_BY="Anupa Shah">
<SUMMARY_OF_RESULTS MODIFIED="2009-02-18 18:38:17 +0000" MODIFIED_BY="Anupa Shah">
<P>Two large randomised multicentre studies (<LINK REF="STD-SST-2004-Group-B" TYPE="STUDY">SST 2004 Group B</LINK>; <LINK REF="STD-SST-2004-Group-N" TYPE="STUDY">SST 2004 Group N</LINK>) found no benefit using submacular surgery compared to observation in patients with or without subretinal haemorrhage for all functional outcomes. Furthermore, there were risks with submacular surgery, particularly retinal detachment which was high in patients with blood occupying at least 50% and obscuring the features of the neovascular lesion (<LINK REF="STD-SST-2004-Group-B" TYPE="STUDY">SST 2004 Group B</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-02-12 16:21:38 +0000" MODIFIED_BY="Anupa Shah">
<P>The two studies comparing surgery with observation (<LINK REF="STD-SST-2004-Group-B" TYPE="STUDY">SST 2004 Group B</LINK>; <LINK REF="STD-SST-2004-Group-N" TYPE="STUDY">SST 2004 Group N</LINK>) were conducted between 1997 and 2003 and included a wide spectrum of patients in terms of lesions size and morphology, but were limited to an upper visual acuity of 20/100 in the study eye. We believe that these studies are still representative of the profile of patients with untreated neovascular AMD, but it is unknown if the effect of surgery would be similar in patients previously treated with photodynamic therapy or, especially, antiangiogenic therapy, which are offered to most patients today (<LINK REF="REF-Vedula-2008" TYPE="REFERENCE">Vedula 2008</LINK>; <LINK REF="REF-Wormald-2007" TYPE="REFERENCE">Wormald 2007</LINK>). We suggest that surgical techniques were acceptably developed in the study period to be representative of modern procedures.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-02-18 18:40:52 +0000" MODIFIED_BY="Anupa Shah">
<P>Using GRADE criteria, the quality of evidence for the primary outcome was high regarding the lack of benefit in terms of protection from visual loss, and it was low regarding visual gain because of statistical imprecision of the relative risk estimate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). In fact, there was no suggestion of benefit in terms of visual gain (RR 95% CI including 1 or no difference) but 95% CI could not exclude a 50% increase of the chance of gaining vision with surgery.</P>
<P>Among secondary outcome measures, analyses of contrast threshold (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) and reading speed (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) did not demonstrate a benefit.</P>
<P>The analysis pooling quality of life data (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) suggested a benefit using submacular surgery, but this was low quality evidence due to the lack of patient masking for this subjective outcome, which is a recognised potential cause of optimistic estimates of efficacy (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>). This may explain the benefit found for quality of life in patients treated with surgery compared to observation, a benefit which could not be demonstrated for the primary outcome visual acuity. Subgroup analyses in <LINK REF="STD-SST-2004-Group-N" TYPE="STUDY">SST 2004 Group N</LINK> and <LINK REF="STD-SST-2004-Group-B" TYPE="STUDY">SST 2004 Group B</LINK> (from which we could not extract data) showed that a benefit was found in people with both bilateral and unilateral AMD. Since vision-related quality of life is related to visual acuity in the better eye, this seems contradictory with the fact that visual acuity did not differ in the treated and control group. However, an alternative explanation could be that other visual function parameters that were not reported, such as central visual field, showed a beneficial effect using surgery.</P>
<P>Evidence concerning the increased risk of cataract and retinal detachment associated with surgery was of high quality (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>We did not comment on the comparison between submacular surgery and laser photocoagulation because this is a small pilot study and the comparison is of little interest for current clinical practice. Furthermore, it has already been described in a Cochrane review on photocoagulation for neovascular AMD (<LINK REF="REF-Virgili-2007" TYPE="REFERENCE">Virgili 2007</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-02-18 18:43:48 +0000" MODIFIED_BY="Anupa Shah">
<P>We believe that no other major studies have been conducted in this field of research, which is of less interest now given the widespread use of antiangiogenic therapy (<LINK REF="REF-Vedula-2008" TYPE="REFERENCE">Vedula 2008</LINK>).</P>
<P>Multiplicity is a special issue in systematic reviews according to <LINK REF="REF-Bender-2008" TYPE="REFERENCE">Bender 2008</LINK>. Among those listed in <LINK REF="REF-Bender-2008" TYPE="REFERENCE">Bender 2008</LINK>, only the category "multiple outcomes" may be considered for this review. Because the review conclusion was based on the primary outcome, a multiplicity issue can arise for the two dichotomisations of visual acuity, i.e. loss or gain of 2 or more lines of vision. Because gain of vision was so rare among both treated and control patients, RR of gain was vary imprecise and was not considered a valid measure of effect. Therefore, only one primary outcome was used to judge treatment efficacy and the risk of bias conclusion related to multiple outcomes is in fact minimised.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-02-18 18:48:54 +0000" MODIFIED_BY="Anupa Shah">
<P>We have personal knowledge of another systematic review published in 2007 on surgery for AMD (<LINK REF="REF-Falkner-2007" TYPE="REFERENCE">Falkner 2007</LINK>). This review included both RCTs, cohort studies and case series published between 1992 and 2004. The authors found 31 studies (765 patients) investigating removal of CNV and 16 studies (264 patients) evaluating the removal of subretinal haemorrhage. <LINK REF="REF-Falkner-2007" TYPE="REFERENCE">Falkner 2007</LINK> did not include RCTs that met our inclusion criteria beyond the studies found by us.</P>
<P>For studies investigating removal of CNV, <LINK REF="REF-Falkner-2007" TYPE="REFERENCE">Falkner 2007</LINK> reported a loss of 2 or more lines of visual acuity in 25% (95% CI: 18% to 32%) of treated patients and an improvement of visual acuity of 2 or more lines in 28% (95% CI: 20% to 37%). For studies investigating removal of subretinal haemorrhage they reported a loss of 2 or more lines of visual acuity in 13% (95% CI: 6% to 19%) of patients and an improvement of visual acuity of 2 or more lines in 62% (95% CI: 48% to 75%). The definition of subretinal haemorrhage in the individual studies was unclear, but the authors reported a wide range of sizes of the haemorrhage.</P>
<P>The authors stated that reporting of adverse events was variable across studies and provide an overall estimate of complications, which was 51% (95% CI: 35% to 68%) for removal of CNV and 37% (17% to 57%) for removal of subretinal haemorrhage.</P>
<P>The authors concluded that the selected case series in this review showed superior results of visual acuity compared to the SST. They commented that the question of whether this is due to selection bias that seems inevitable when dealing with medium-sized non-randomised case series or due to better results in single centres cannot be answered and that there still seemed to be indications for macular surgery such as in patients with AMD with low preoperative visual acuity due to large haemorrhagic or fibrotic membranes or non-responders to photodynamic therapy.</P>
<P>It is difficult to compare the results of our review, which included only RCTs, with those of <LINK REF="REF-Falkner-2007" TYPE="REFERENCE">Falkner 2007</LINK>. Furthermore, systematic reviews of case series are difficult to conduct because the methodology is not well developed and standardised yet. It is also difficult to incorporate the information on the rate of adverse events presented in <LINK REF="REF-Falkner-2007" TYPE="REFERENCE">Falkner 2007</LINK> in our review, because the study authors have given no detailed description of each type of complication.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-12-02 13:28:09 +0000" MODIFIED_BY="Gianni Virgili">
<IMPLICATIONS_PRACTICE MODIFIED="2008-12-02 13:24:59 +0000" MODIFIED_BY="Gianni Virgili">
<P>There is high quality evidence suggesting that submacular surgery does not prevent visual loss compared to observation, and there is low quality evidence suggesting little chance of visual gain in people treated with surgery for neovascular AMD and subfoveal CNV with or without extensive blood, who are similar to those included in the studies of this review. There is high quality evidence that there are increased risks using submacular surgery because complications can arise after surgery, such as cataract and retinal detachment.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-12-02 13:28:09 +0000" MODIFIED_BY="Gianni Virgili">
<P>Further research on submacular surgery in people with macular lesions such as most of those included in these studies is not recommended. The potential additional benefit due to technological developments in vitreoretinal surgery cannot be assessed in this review.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-02-18 18:50:55 +0000" MODIFIED_BY="Anupa Shah">
<P>We acknowledge the Trials Search Co-ordinator for CEVG, for devising and running the electronic searches. We thank Anupa Shah, Review Group Co-ordinator for CEVG and the peer referees Catey Bunce and Francesco Boscia for their assistance and comments and Jennifer Evans for her editorial support. We also thank Barbara Hawkins (Baltimore, MD) for providing additional information and data on the SST studies. Finally, we are grateful to the CEVG AMD Consumer Panel (David Brandon, Harold Burton, Bill Crowther, Jan Elson, Brenda Rogers, Bob Thomas) for their comments on the abstract and plain language summary of the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Fabrizio Giansanti: grants for participation at meetings from Allergan, Novartis and Pfizer.<BR/>Chiara Eandi: grants for participation at meetings from Novartis.<BR/>Gianni Virgili: grants for participation at meetings from Allergan, Novartis and Pfizer; paid participation in advisory boards for Novartis and Pfizer.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-02-12 16:41:45 +0000" MODIFIED_BY="Anupa Shah">
<P>Conceiving the review: CE, FG, GV<BR/>Designing the review: CE, FG, GV<BR/>Co-ordinating the review: FG<BR/>Data collection for the review<BR/>- Designing electronic search strategies: Cochrane Eyes and Vision Group editorial base<BR/>- Undertaking manual searches: FG<BR/>- Screening search results: FG, CE<BR/>- Organising retrieval of papers: FG<BR/>- Screening retrieved papers against inclusion criteria: CE, FG, GV<BR/>- Appraising quality of papers: CE, FG, GV<BR/>- Extracting data from papers: FG<BR/>- Writing to authors of papers for additional information: FG<BR/>- Providing additional data about papers: FG<BR/>- Obtaining and screening data on unpublished studies: FG<BR/>Data management for the review<BR/>- Entering data into RevMan: FG, GV<BR/>- Analysis of data: FG, GV<BR/>Interpretation of data<BR/>- Providing a methodological perspective: GV<BR/>- Providing a clinical perspective: CE, FG, GV<BR/>- Providing a policy perspective: CE, FG, GV<BR/>- Providing a consumer perspective: Cochrane Eyes and Vision Group AMD Consumer Panel<BR/>Writing the review: FG, CE, GV<BR/>Providing general advice on the review: GV<BR/>Securing funding for the review: FG<BR/>Guarantor for review: FG</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-02-18 19:09:58 +0000" MODIFIED_BY="Anupa Shah">
<P>The risk of bias tables were introduced by the Cochrane Collaboration after the protocol had been published.</P>
<P>The section "Outcomes included in the Summary of Findings Table" at the end of the "Types of outcome measures" section was not included in the protocol since the Summary of Findings table was not available in the RevMan version used when the protocol for this review was written. Therefore, the selection of the outcomes to be included in the Summary of Findings table was not prespecified.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-02-18 19:17:45 +0000" MODIFIED_BY="Anupa Shah">
<STUDIES MODIFIED="2009-02-13 15:52:11 +0000" MODIFIED_BY=" Iris Gordon">
<INCLUDED_STUDIES MODIFIED="2009-02-13 15:52:11 +0000" MODIFIED_BY=" Iris Gordon">
<STUDY DATA_SOURCE="PUB" ID="STD-SST-2000" MODIFIED="2009-02-13 15:52:11 +0000" MODIFIED_BY=" Iris Gordon" NAME="SST 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-13 15:52:11 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: II. Quality of life outcomes submacular surgery trials pilot study report number 2</TI>
<SO>American Journal of Ophthalmology 2000</SO>
<YR>2000</YR>
<VL>130</VL>
<NO>4</NO>
<PG>408-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-13 15:50:07 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bressler NM, Bressler SB, Hawkins BS, Marsh MJ, Sternberg P Jr, Thomas MA. Submacular Surgery Trials Pilot Study Investigators</AU>
<TI>Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2000</YR>
<VL>130</VL>
<NO>4</NO>
<PG>387-407</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SST-2004-Group-B" MODIFIED="2009-02-13 15:33:15 +0000" MODIFIED_BY=" Iris Gordon" NAME="SST 2004 Group B" YEAR="2004">
<REFERENCE MODIFIED="2009-02-13 15:33:15 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bressler NM, Bressler SB, Childs AL, Haller JA, Hawkins BS, Lewis H, et al. Submacular Surgery Trials (SST) Research Group</AU>
<TI>Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13</TI>
<SO>Ophthalmology</SO>
<YR>2004</YR>
<VL>111</VL>
<NO>11</NO>
<PG>1993-2006</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SST-2004-Group-N" MODIFIED="2009-02-13 15:35:52 +0000" MODIFIED_BY=" Iris Gordon" NAME="SST 2004 Group N" YEAR="2004">
<REFERENCE MODIFIED="2009-02-13 15:35:52 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkins BS, Bressler NM, Miskala PH, Bressler SB, Holekamp NM, Marsh MJ, et al. Submacular Surgery Trials (SST) Research Group</AU>
<TI>Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11</TI>
<SO>Ophthalmology</SO>
<YR>2004</YR>
<VL>111</VL>
<NO>11</NO>
<PG>1967-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES MODIFIED="2008-12-06 17:27:52 +0000" MODIFIED_BY="Gianni Virgili">
<STUDY DATA_SOURCE="UNPUB" ID="STD-SST-Group-B-pilot-trial" MODIFIED="2008-12-06 17:27:52 +0000" MODIFIED_BY="Gianni Virgili" NAME="SST Group B pilot trial" YEAR="1995">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SST-Group-N-pilot-trial" MODIFIED="2008-12-06 17:27:28 +0000" MODIFIED_BY="Gianni Virgili" NAME="SST Group N pilot trial" YEAR="1995">
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-02-18 19:17:45 +0000" MODIFIED_BY="Anupa Shah">
<ADDITIONAL_REFERENCES MODIFIED="2009-02-18 19:17:45 +0000" MODIFIED_BY="Anupa Shah">
<REFERENCE ID="REF-Bender-2008" MODIFIED="2009-02-13 14:29:17 +0000" MODIFIED_BY=" Iris Gordon" NAME="Bender 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bendera R, Bunce C, Clarke M, Gates S, Lange S, Pace NL, et al</AU>
<TI>Attention should be given to multiplicity issues in systematic reviews</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>9</NO>
<PG>857-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berger-1992" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Berger 1992" TYPE="JOURNAL_ARTICLE">
<AU>Berger AS, Kaplan HJ</AU>
<TI>Clinical experience with surgical removal of subfoveal neovascular membranes. Short-term postoperative results</TI>
<SO>Ophthalmology</SO>
<YR>1992</YR>
<VL>99</VL>
<NO>6</NO>
<PG>969-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blinder-1991" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Blinder 1991" TYPE="JOURNAL_ARTICLE">
<AU>Blinder KJ, Peyman GA, Paris CL, Gremillion CM Jr</AU>
<TI>Submacular scar excision in age-related macular degeneration</TI>
<SO>International Ophthalmology</SO>
<YR>1991</YR>
<VL>15</VL>
<NO>4</NO>
<PG>215-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bunce-2006" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Bunce 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bunce C, Wormald R</AU>
<TI>Leading causes of certification for blindness and partial sight in England &amp; Wales</TI>
<SO>BMC Public Health</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Juan-1989" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="de Juan 1989" TYPE="JOURNAL_ARTICLE">
<AU>de Juan E Jr, Machemer R</AU>
<TI>Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1988</YR>
<VL>105</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2008" MODIFIED="2009-02-13 14:33:28 +0000" MODIFIED_BY=" Iris Gordon" NAME="Deeks 2008" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-2006" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Evans 2006" TYPE="COCHRANE_REVIEW">
<AU>Evans JR</AU>
<TI>Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000254. DOI: 10.1002/14651858.CD000254.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Evans-2009" MODIFIED="2009-02-18 17:50:33 +0000" MODIFIED_BY="Anupa Shah" NAME="Evans 2009" TYPE="COCHRANE_PROTOCOL">
<AU>Evans JR, Virgili G, Gordon I, Bunce C, Chakravarthy U, Desai P, Fletcher A</AU>
<TI>Interventions for neovascular age-related macular degeneration</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-02-18 17:49:41 +0000" MODIFIED_BY="Anupa Shah">
<IDENTIFIER MODIFIED="2009-02-18 17:49:41 +0000" MODIFIED_BY="Anupa Shah" TYPE="DOI" VALUE="10.1002/14651858.CD007650"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Falkner-2007" MODIFIED="2009-02-16 19:21:57 +0000" MODIFIED_BY="Anupa Shah" NAME="Falkner 2007" TYPE="JOURNAL_ARTICLE">
<AU>Falkner CI, Leitich H, Frommlet F, Bauer P, Binder S</AU>
<TI>The end of submacular surgery for age-related macular degeneration? A meta-analysis</TI>
<SO>Graefes Archive for Clinical &amp; Experimental Ophthalmology</SO>
<YR>2007</YR>
<VL>254</VL>
<NO>4</NO>
<PG>490-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedman-2004" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Friedman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al</AU>
<TI>Prevalence of age-related macular degeneration in the United States</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2004</YR>
<VL>122</VL>
<NO>4</NO>
<PG>564-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" MODIFIED="2008-12-19 18:33:20 +0000" MODIFIED_BY="Gianni Virgili" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>8</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haupert-2001" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Haupert 2001" TYPE="JOURNAL_ARTICLE">
<AU>Haupert CL, McCuen BW, Jaffe GJ, Steuer ER, Cox TA, Toth CA, et al</AU>
<TI>Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2001</YR>
<VL>131</VL>
<NO>2</NO>
<PG>208-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herriot-1997" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Herriot 1997" TYPE="CONFERENCE_PROC">
<AU>Herriot WJ</AU>
<SO>Further experience in management of submacular hemorrhage with intravitreal t-PA. Proceeding of 1997 update on macular surgery ; 1997 Oct 26-29</SO>
<YR>1997</YR>
<PG>82-4</PG>
<PB>American Academy Ophthalmology</PB>
<CY>San Francisco</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008a" MODIFIED="2009-02-18 19:17:45 +0000" MODIFIED_BY="Anupa Shah" NAME="Higgins 2008a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008b" MODIFIED="2009-02-18 19:17:29 +0000" MODIFIED_BY="Anupa Shah" NAME="Higgins 2008b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics</TI>
<SO>In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-2002" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Klein 2002" TYPE="JOURNAL_ARTICLE">
<AU>Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH</AU>
<TI>Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study</TI>
<SO>Ophthalmology</SO>
<YR>2002</YR>
<VL>109</VL>
<NO>10</NO>
<PG>1767-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krzystolik-2005" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Krzystolik 2005" TYPE="COCHRANE_REVIEW">
<AU>Krzystolik MG, Woodcome HA, Reddy U</AU>
<TI>Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD005139. DOI: 10.1002/14651858.CD005139"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lambert-1992" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Lambert 1992" TYPE="JOURNAL_ARTICLE">
<AU>Lambert HM, Capone A Jr, Aaberg TM, Sternberg P Jr, Mandell BA, Lopez PF</AU>
<TI>Surgical excision of subfoveal neovascular membranes in age-related macular degeneration</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1992</YR>
<VL>113</VL>
<NO>3</NO>
<PG>257-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leibowitz-1980" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Leibowitz 1980" TYPE="JOURNAL_ARTICLE">
<AU>Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, et al</AU>
<TI>The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975</TI>
<SO>Survey of Ophthalmology</SO>
<YR>1980</YR>
<VL>24</VL>
<NO>Suppl</NO>
<PG>335-610</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Machemer-1993" MODIFIED="2009-02-13 14:57:15 +0000" MODIFIED_BY=" Iris Gordon" NAME="Machemer 1993" TYPE="JOURNAL_ARTICLE">
<AU>Machemer R, Steinhorst UH</AU>
<TI>Retinal separation, retinotomy and macular relocation. II. A surgical approach for age-related macular degeneration</TI>
<SO>Graefes Archive for Clinical &amp; Experimental Ophthalmology</SO>
<YR>1993</YR>
<VL>231</VL>
<NO>11</NO>
<PG>635-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitchell-1995" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Mitchell 1995" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell P, Smith W, Attebo K, Wang JJ</AU>
<TI>Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study</TI>
<SO>Ophthalmology</SO>
<YR>1995</YR>
<VL>102</VL>
<NO>10</NO>
<PG>1450-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohji-1998" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Ohji 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ohji M, Saito Y, Hayashi A, Lewis Jm, Tano Y</AU>
<TI>Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1998</YR>
<VL>116</VL>
<NO>10</NO>
<PG>1326-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Owen-2003" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Owen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Owen CG, Fletcher AE, Donoghue M, Rudnicka AR</AU>
<TI>How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2003</YR>
<VL>87</VL>
<NO>3</NO>
<PG>312-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patel-2008" MODIFIED="2009-02-16 19:21:16 +0000" MODIFIED_BY="Anupa Shah" NAME="Patel 2008" TYPE="JOURNAL_ARTICLE">
<AU>Patel PJ, Chen FK, Rubin GS, Tufail A</AU>
<TI>Intersession repeatability of visual acuity scores in age-related macular degeneration</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2008</YR>
<VL>49</VL>
<NO>10</NO>
<PG>4347-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-1992" MODIFIED="2008-12-19 18:33:20 +0000" MODIFIED_BY="Gianni Virgili" NAME="Thomas 1992" TYPE="JOURNAL_ARTICLE">
<AU>Thomas MA, Grand MG, Williams DF, Lee CM, Pesin SR, Lowe MA</AU>
<TI>Surgical management of subfoveal choroidal neovascularization</TI>
<SO>Ophthalmology</SO>
<YR>1992</YR>
<VL>99</VL>
<NO>6</NO>
<PG>952-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ting-2002" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Ting 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ting TD, Oh M, Cox TA, Meyer CH, Toth CA</AU>
<TI>Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2002</YR>
<VL>120</VL>
<NO>6</NO>
<PG>731-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Kerckhoven-2001" MODIFIED="2008-12-19 18:33:19 +0000" MODIFIED_BY="Gianni Virgili" NAME="Van Kerckhoven 2001" TYPE="JOURNAL_ARTICLE">
<AU>Van Kerckhoven W, Lafaut B, Follens I, De Laey JJ</AU>
<TI>Features of age-related macular degeneration on optical coherence tomography</TI>
<SO>Bulletin de la Societe Belge d'Ophtalmologie</SO>
<YR>2001</YR>
<VL>281</VL>
<PG>75-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vedula-2008" MODIFIED="2009-02-13 15:09:02 +0000" MODIFIED_BY=" Iris Gordon" NAME="Vedula 2008" TYPE="COCHRANE_REVIEW">
<AU>Vedula SS, Krzystolik MG</AU>
<TI>Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-02-13 15:09:02 +0000" MODIFIED_BY=" Iris Gordon">
<IDENTIFIER MODIFIED="2009-02-13 15:09:02 +0000" MODIFIED_BY=" Iris Gordon" TYPE="DOI" VALUE="Art. No.: CD005139. DOI: 10.1002/14651858.CD005139.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Virgili-2007" MODIFIED="2008-12-19 18:33:20 +0000" MODIFIED_BY="Gianni Virgili" NAME="Virgili 2007" TYPE="COCHRANE_REVIEW">
<AU>Virgili G, Bini A</AU>
<TI>Laser photocoagulation for neovascular age-related macular degeneration</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD004763. DOI: 10.1002/14651858.CD004763.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2009-02-13 16:07:50 +0000" MODIFIED_BY=" Iris Gordon" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2009-02-13 16:07:50 +0000" MODIFIED_BY=" Iris Gordon"/>
</REFERENCE>
<REFERENCE ID="REF-Wormald-2007" MODIFIED="2009-02-13 15:18:12 +0000" MODIFIED_BY=" Iris Gordon" NAME="Wormald 2007" TYPE="COCHRANE_REVIEW">
<AU>Wormald R, Evans J, Smeeth L, Henshaw K</AU>
<TI>Photodynamic therapy for neovascular age-related macular degeneration</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-02-13 15:18:12 +0000" MODIFIED_BY=" Iris Gordon">
<IDENTIFIER MODIFIED="2009-02-13 15:18:12 +0000" MODIFIED_BY=" Iris Gordon" TYPE="DOI" VALUE="Art. No.: CD002030. DOI: 10.1002/14651858.CD002030.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-02-18 19:16:00 +0000" MODIFIED_BY="Anupa Shah">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-02-18 19:16:00 +0000" MODIFIED_BY="Anupa Shah" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-02-12 16:42:15 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-SST-2000">
<CHAR_METHODS MODIFIED="2008-12-16 10:58:46 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomisation sequence generation: generated by computer based on randomly permuted blocks of randomly selected sizes.</P>
<P>Allocation concealment: patient and eye eligibility reviewed with the ophthalmologist before the random assignment to the surgery or laser arm was communicated over the telephone by Co-ordinating Centre personnel who made assignments sequentially from lists prepared at the Co-ordinating Centre.</P>
<P>Masking: masked examiner for visual function measures (visual acuity, contrast sensitivity, reading ability); masked quality-of-life interviewer; unmasked anatomic outcome assessor (due to recognisable fundus changes related to the interventions). Patients and care providers unmasked.</P>
<P>Exclusions after randomisation: not reported.</P>
<P>Losses to follow up: 2 patients died in both arms during the second year of follow-up; completeness of examinations: 95% laser and 90% surgery; at 12 months 34/36 in laser arm and 31/34 in surgery arm.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-22 11:11:28 +0000" MODIFIED_BY="Anupa Shah">
<P>Country: USA, 15 centres. Number randomised: 70 eyes of 70 patients.</P>
<P>Inclusion criteria: 1) subfoveal recurrent neovascular lesion following earlier laser photocoagulation of extrafoveal or juxtafoveal choroidal neovascularization; 2) some classic CNV; 3) total size of the lesion no larger than 9.0 disk areas; 4) visual acuity 20/64 to 20/800.</P>
<P>Exclusion criteria: earlier submacular surgery or vitrectomy for any reason in the candidate study eye.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-16 11:00:37 +0000" MODIFIED_BY="Anupa Shah">
<P>Treatment: submacular surgery with the goal of removing the entire choroidal neovascular lesion, including CNV (classic and occult), blood, and laser lesion.<BR/>Control: laser photocoagulation in accordance with the Macular Photocoagulation Study protocol Duration: 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-09 14:05:33 +0000" MODIFIED_BY="Gianni Virgili">
<P>Functional: ETDRS visual acuity; reading speed; contrast threshold.</P>
<P>Anatomic: lesion size.</P>
<P>Quality of life (National Eye Institute-Visual Function Questionnaire).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-09 14:06:05 +0000" MODIFIED_BY="Gianni Virgili">
<P>Funding: from the National Eye Institute of the National Institutes of Health, Bethesda, Maryland, and by donations to the Submacular Surgery Trials Research Fund from Alcon, Ft. Worth, Texas; other not-for-profit funding.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-18 19:10:56 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-SST-2004-Group-B">
<CHAR_METHODS MODIFIED="2009-02-18 19:10:56 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomisation sequence generation: computer generated random numbers in blocks of random size (4 and 8 assignments per block), stratified by clinical cent er, and baseline visual acuity (better than 20/200 or 20/200 or worse) (information provided by the authors).</P>
<P>Allocation concealment: allocations were made during a telephone call to the Co-ordinating Centre after the baseline data forms had been faxed to the Co-ordinating Centre, the baseline QoL telephone interview had been completed, and the eligibility checklist, which included the patient's study ID and name code, and the signed consent form had been faxed to the Co-ordinating Centre (information provided by the authors).</P>
<P>Masking: masked examiner for visual function measures (visual acuity, contrast sensitivity, reading ability); masked quality-of-life interviewer; unmasked anatomic outcome assessor (due to recognisable fundus changes related to the interventions). Patients and care providers unmasked.</P>
<P>Exclusions after randomisation: not reported.</P>
<P>Losses to follow-up at 1 year: completed examinations 139/160 (87%) in the observation arm, 152/163 (93%) in the surgery arm.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-16 11:44:05 +0000" MODIFIED_BY="Anupa Shah">
<P>Country: USA (multicentre study), Patients randomised: 336</P>
<P>Inclusion criteria: 1) AMD patients with predominantly haemorrhagic subfoveal lesions in which at least 50% of the choroidal neovascular lesion was occupied by blood thick enough to limit the examining ophthalmologist&#8217;s ability to determine whether the area of blood also was occupied by CNV; 2) the total area of any classic and occult CNV visible on the fluorescein angiogram no greater than 9 disc areas, even though the entire lesion, including all areas of blood considered components of the lesion, had no size limit as long as the entire lesion was larger than 3.5 disc areas and at least 75% of the blood was posterior to the equator; 3) visual acuity of 20/100 or worse but at least light perception.</P>
<P>Exclusion criteria: other ocular conditions causing CNV or progressive visual loss.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-16 11:43:16 +0000" MODIFIED_BY="Anupa Shah">
<P>Surgical procedure: the clot and any associated fibrovascular tissue were extracted mechanically whenever possible, based on the judgment of the surgeon. At the discretion of the surgeon, 10 to 12.5 g of recombinant tPA in 0.1 ml could be injected into the haemorrhagic lesion before removal of the blood. Whenever blood was encountered beneath the retinal pigment epithelium, 10 to 12.5 g of tPA in 0.1 ml could be injected beneath the RPE at the discretion of the surgeon.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-11 21:53:18 +0000" MODIFIED_BY="Gianni Virgili">
<P>Functional: visual acuity, contrast sensitivity, reading speed.</P>
<P>Anatomic: leakage from CNV, lesion size.</P>
<P>Quality of life: National Eye Institute Visual Functioning Questionnaire (NEI-VFQ), 36-item Health Status Survey (Short Form 36), the Hospital Anxiety and Depression Scale (HADS), and the SST Vision Preference Value Scale (SST-VPVS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-16 11:42:45 +0000" MODIFIED_BY="Anupa Shah">
<P>Beginning in April 2000, photodynamic therapy with verteporfin also could be used to treat CNV during follow-up. Eyes in the observation arm could receive laser photocoagulation or, after April 2000, photodynamic therapy with verteporfin during follow-up if, as blood cleared, a lesion was noted for which one of these treatments was judged to be beneficial, compared with no treatment.</P>
<P>Although 55% of the surgery eyes had fluorescein leakage from CNV observed on at least 1 set of follow-up photographs, only 19% had received additional treatment by the 24-month examination given treatment indications. Laser photocoagulation was applied to 20 of the 32 surgery eyes retreated; 6 surgery eyes had repeat surgery. By the 24-month examination, 12% of the observation eyes had received treatment prompted by fluorescein leakage from CNV observed as blood cleared.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-18 19:16:00 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-SST-2004-Group-N">
<CHAR_METHODS MODIFIED="2009-02-18 19:11:26 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomisation sequence generation: computer generated random numbers in blocks of random size (4 and 8 assignments per block), stratified by clinical cent er, and baseline visual acuity (better than 20/200 or 20/200 or worse) (information provided by the authors).</P>
<P>Allocation concealment: for those who agreed to participate, a study identification number and an alphabetic code were assigned before they completed an interview by telephone with personnel at the SST Co-ordinating Centre (Baltimore, Maryland). After the patient signed the consent form for the trial, the identification number and alphabetic code were recorded on the baseline data forms, which were telecopied to the Coordinating Centre for preliminary review of eligibility and completeness of baseline data recording. The next treatment arm assignment was selected from the file of random assignments that had been prepared for that clinical centre specifically for the SST Group N Trial and for the VA of the study eye (20/200 [20/100 to 20/160] or 20/200 [20/200 to 20/800]). The clinical centre staff were notified of the assigned treatment, surgery or observation, by means of an automated message returned to them by telecopier. The assignment was communicated to the patient by the enrolling ophthalmologist; surgery was scheduled as soon as possible for each patient assigned to that treatment arm.</P>
<P>Masking: masked examiner for visual function measures (visual acuity, contrast sensitivity, reading ability); masked quality-of-life interviewer; unmasked anatomic outcome assessor (due to recognisable fundus changes related to the interventions). Patients and care providers unmasked.</P>
<P>Loss to follow-up: 30  patients (13%) in the observation arm and 28 in the surgery arm (12%) died after enrolment; among the 19 patients (8%) in the observation arm vs. 8 in the surgery arm (4%) missed the 24-month examination. At 1 year, 214/226 in the surgery arm compared to 210/228 in the observation arm were analysed.</P>
<P>Data for ineligible patients 38, (11%) were analysed with data from all other patients in the treatment arm to which they were assigned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-16 11:37:36 +0000" MODIFIED_BY="Anupa Shah">
<P>Country: USA (multicentre study), Patients randomised: 454.</P>
<P>Inclusion criteria: 1) subfoveal neovascular lesion, some part of which was classic CNV. The subfoveal lesion could contain occult CNV or blood as components. However, the component located under the geometric cent er of the foveal avascular zone was required to be CNV (either classic or occult). Furthermore, any contiguous blood had to occupy less than half the total area occupied by the subfoveal lesion. Prior treatment for CNV or any other macular condition or earlier vitrectomy for any reason rendered an eye ineligible. The size of the total lesion, including contiguous blood, if any, could not exceed 9.0 disc areas. Eyes with lesions smaller than 3.5 disc areas were eligible only when the lesion boundaries were poorly demarcated (i.e., the eye was an unsuitable candidate for laser photocoagulation). 3) visual acuity 20/100 to 20/800 inclusive.</P>
<P>Exclusion criteria: other ocular conditions causing CNV or progressive visual loss.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-18 19:16:00 +0000" MODIFIED_BY="Anupa Shah">
<P>Surgical procedure: standard three-port pars plana vitrectomy and surgical detachment of the posterior hyaloid when not already detached preoperatively. The retinotomy site was chosen by the surgeon to provide optimal access to the neovascular lesion and to minimize surgical trauma to the fovea. Surgeons had the option of infusing balanced saline solution to separate the neurosensory retina from the neovascular lesion. Fibrovascular tissue was removed manually from the subretinal space with a microforceps. Intraocular pressure was elevated immediately before removal of the tissue from beneath the retina to minimise haemorrhage from the choroid and was returned to normal before removal of the neovascular tissue from the eye.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-11 21:53:01 +0000" MODIFIED_BY="Gianni Virgili">
<P>Functional: visual acuity, contrast sensitivity, reading speed.</P>
<P>Anatomic: leakage from CNV, lesion size.</P>
<P>Quality of life: National Eye Institute Visual Functioning Questionnaire (NEI-VFQ), 36-item Health Status Survey (Short Form 36), the Hospital Anxiety and Depression Scale (HADS), and the SST Vision Preference Value Scale (SST-VPVS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-16 11:37:38 +0000" MODIFIED_BY="Anupa Shah">
<P>In December 1999, shortly after 1-year findings from the trials of photodynamic therapy with verteporfin were published showing that the new treatment was effective for a subset of patients eligible for the Group N Trial, the Data and Safety Monitoring Committee recommended that the SST Research Group revise the consent forms for future patients eligible for the Group N Trial, evaluate all Group N Trial patients for eligibility for photodynamic therapy with verteporfin, and permit the new treatment to be used to manage CNV during follow-up.</P>
<P>During follow-up 44 eyes had laser photocoagulation to recurrent CNV, and 7 had photodynamic therapy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AMD: age-related macular degeneration<BR/>CNV: choroidal neovascularisation<BR/>ETDRS: early treatment diabetic retinopathy study<BR/>SST: Submacular Surgery Trials<BR/>VA: visual acuity</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-12-16 11:08:32 +0000" MODIFIED_BY="Anupa Shah" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2008-12-16 11:08:08 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-SST-Group-B-pilot-trial">
<CHAR_METHODS MODIFIED="2008-12-16 11:08:08 +0000" MODIFIED_BY="Anupa Shah">
<P>Similar to the fullscale SST Group B trial. Randomisation was centralised and assignments were not revealed until after eligibility had been established and written informed consent provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-12 17:01:14 +0000" MODIFIED_BY="Gianni Virgili">
<P>Randomised: 47 surgery, 46 observation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-12 17:01:14 +0000" MODIFIED_BY="Gianni Virgili">
<P>Similar to the fullscale SST Group B trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-12 17:01:14 +0000" MODIFIED_BY="Gianni Virgili">
<P>Visual acuity was obtained by a masked examiner.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-12 17:01:14 +0000" MODIFIED_BY="Gianni Virgili">
<P>Mean best corrected visual acuity was 20/500 for 41 treated patients (46 alive) and 20/400 for 30 observed patients (43 alive) at 1 year.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-12-16 11:08:32 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-SST-Group-N-pilot-trial">
<CHAR_METHODS MODIFIED="2008-12-16 11:08:32 +0000" MODIFIED_BY="Anupa Shah">
<P>Similar to the fullscale SST Group N trial. Randomisation was centralised and assignments were not revealed until after eligibility had been established and written informed consent provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-12 17:01:14 +0000" MODIFIED_BY="Gianni Virgili">
<P>Randomised: 79 surgery, 78 observation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-12 17:01:14 +0000" MODIFIED_BY="Gianni Virgili">
<P>Similar to the fullscale SST Group N trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-12 17:01:14 +0000" MODIFIED_BY="Gianni Virgili">
<P>Visual acuity was obtained by a masked examiner.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-12 17:01:14 +0000" MODIFIED_BY="Gianni Virgili">
<P>Mean best corrected visual acuity was 20/320 for 65 treated patients (77 alive) and 20/400 for 66 observed patients (77 alive) at 1 year.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-12-16 11:31:34 +0000" MODIFIED_BY="Anupa Shah">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-11-09 14:12:00 +0000" MODIFIED_BY="Gianni Virgili" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-09 14:04:33 +0000" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2000">
<DESCRIPTION>
<P>Computer-generated numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-09 13:49:43 +0000" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2004-Group-B">
<DESCRIPTION>
<P>Computer-generated numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-09 14:12:00 +0000" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2004-Group-N">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-12-16 11:31:28 +0000" MODIFIED_BY="Anupa Shah" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-16 11:00:53 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-SST-2000">
<DESCRIPTION>
<P>Randomisation performed by the Co-ordinating Centre after eligibility was assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-16 11:31:28 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-SST-2004-Group-B">
<DESCRIPTION>
<P>Randomisation performed by the Co-ordinating Centre after eligibility was assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-16 11:31:03 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-SST-2004-Group-N">
<DESCRIPTION>
<P>Randomisation performed by the Co-ordinating Centre after eligibility was assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-12-16 11:31:34 +0000" MODIFIED_BY="Anupa Shah" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3" REF_IDS="CMP-001.05">
<NAME>Quality of life</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2" REF_IDS="CMP-001.08">
<NAME>Anatomic outcome</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.03 CMP-001.04">
<NAME>Functional outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-16 11:01:02 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-SST-2000">
<DESCRIPTION>
<P>Vision examiners were masked. Study patients, co-ordinators, and ophthalmologists were not masked.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-12-16 11:01:07 +0000" MODIFIED_BY="Anupa Shah" RESULT="NO" STUDY_ID="STD-SST-2000">
<DESCRIPTION>
<P>Personnel at the Photograph Reading Centre were masked to the treatment assignment when evaluating baseline photographs but not when evaluating follow-up photographs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-12-16 11:01:15 +0000" MODIFIED_BY="Anupa Shah" RESULT="NO" STUDY_ID="STD-SST-2000">
<DESCRIPTION>
<P>Interviews were administered by telephone from the SST Co-ordinating Centre and were conducted by trained interviewers who were masked to treatment assignment, study eye, and clinical data. However, patients were not masked and this is critical for a subjective outcome like quality of life.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-16 11:31:34 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-SST-2004-Group-B">
<DESCRIPTION>
<P>Vision examiners were masked. Study patients, co-ordinators, and ophthalmologists were not masked.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-12-16 11:30:34 +0000" MODIFIED_BY="Anupa Shah" RESULT="NO" STUDY_ID="STD-SST-2004-Group-B">
<DESCRIPTION>
<P>Personnel at the Photograph Reading Centre were masked to the treatment assignment when evaluating baseline photographs but not when evaluating follow-up photographs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-12-16 11:31:22 +0000" MODIFIED_BY="Anupa Shah" RESULT="NO" STUDY_ID="STD-SST-2004-Group-B">
<DESCRIPTION>
<P>Interviews were administered by telephone from the SST Co-ordinating Centre and were conducted by trained interviewers who were masked to treatment assignment, study eye, and clinical data. However, patients were not masked and this is critical for a subjective outcome like quality of life.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-16 11:30:56 +0000" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-SST-2004-Group-N">
<DESCRIPTION>
<P>Vision examiners were masked. Study patients, co-ordinators, and ophthalmologists were not masked.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-12-16 11:30:42 +0000" MODIFIED_BY="Anupa Shah" RESULT="NO" STUDY_ID="STD-SST-2004-Group-N">
<DESCRIPTION>
<P>Personnel at the Photograph Reading Centre were masked to the treatment assignment when evaluating baseline photographs but not when evaluating follow-up photographs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-12-16 11:30:51 +0000" MODIFIED_BY="Anupa Shah" RESULT="NO" STUDY_ID="STD-SST-2004-Group-N">
<DESCRIPTION>
<P>Interviews were administered by telephone from the SST Co-ordinating Centre and were conducted by trained interviewers who were masked to treatment assignment, study eye, and clinical data. However, patients were not masked and this is critical for a subjective outcome like quality of life.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-11-09 14:06:56 +0000" MODIFIED_BY="Gianni Virgili" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-09 14:06:56 +0000" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2000">
<DESCRIPTION>
<P>Loss of follow-up was limited and balanced in the two study arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-06 12:10:24 +0100" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2004-Group-B">
<DESCRIPTION>
<P>Lost to follow-up was modest, compared to the frequency of primary outcomes, and balanced in the two arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-06 12:41:57 +0100" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2004-Group-N">
<DESCRIPTION>
<P>Lost to follow-up was modest, compared to the frequency of primary outcomes, and balanced in the two arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-11-09 14:08:39 +0000" MODIFIED_BY="Gianni Virgili" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-09 14:08:39 +0000" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2000">
<DESCRIPTION>
<P>Outcomes are fully reported and a study protocol is mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-06 12:11:36 +0100" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2004-Group-B">
<DESCRIPTION>
<P>Outcomes are fully reported and a study protocol is mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-06 12:42:43 +0100" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2004-Group-N">
<DESCRIPTION>
<P>Outcomes are fully reported and a study protocol is mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-11-09 14:10:18 +0000" MODIFIED_BY="Gianni Virgili" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-09 14:10:18 +0000" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2000">
<DESCRIPTION>
<P>National Eye Institute sponsored trial and several other not-for-profit funding sources; only one commercial sponsor with potential interest in study intervention; no other type of bias known.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-06 12:12:33 +0100" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2004-Group-B">
<DESCRIPTION>
<P>National Eye Institute sponsored trial; no other type of bias known.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-06 12:42:47 +0100" MODIFIED_BY="Gianni Virgili" RESULT="YES" STUDY_ID="STD-SST-2004-Group-N">
<DESCRIPTION>
<P>National Eye Institute sponsored trial; no other type of bias known.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-02-12 16:20:47 +0000" MODIFIED_BY="Anupa Shah">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-02-12 16:20:47 +0000" MODIFIED_BY="Anupa Shah" NO="1" READONLY="YES">
<TITLE MODIFIED="2008-12-06 16:45:55 +0000" MODIFIED_BY="Grade Profiler">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="29">
<TR>
<TD COLSPAN="7">
<P>
<B>macular surgery compared to observation for choroidal neovascularisation secondary to age-related macular degeneration</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with choroidal neovascularisation secondary to age-related macular degeneration</P>
<P>
<B>Settings:</B>
</P>
<P>
<B>Intervention:</B> macular surgery</P>
<P>
<B>Comparison: </B>observation</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>observation</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>macular surgery</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Visual loss of 2+ lines at 1 year</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.96 </B>
<BR/>(0.84 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>715<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>574 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>551 per 1000</B>
<BR/>(482 to 626)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Visual gain of 2+ lines at 1 year</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.06 </B>
<BR/>(0.75 to 1.5)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>715<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>114 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>121 per 1000</B>
<BR/>(85 to 171)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>187 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>198 per 1000</B>
<BR/>(140 to 281)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Contrast threshold loss -0.15 log units or more at 1 year</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.8 </B>
<BR/>(0.63 to 1.02)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>689<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>180 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>144 per 1000</B>
<BR/>(113 to 184)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>440 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>352 per 1000</B>
<BR/>(277 to 449)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Reading speed 40 word/minute or more after 1 year</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.88 </B>
<BR/>(0.64 to 1.2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>692<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>201 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>177 per 1000</B>
<BR/>(129 to 241)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Loss of 6+ points of overall NEI-VFQ score at 1 year</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.35 </B>
<BR/>(1.09 to 1.68)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>689<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>282 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>381 per 1000</B>
<BR/>(307 to 474)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events: cataract surgery at 1 year</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 8.69 </B>
<BR/>(4.06 to 18.61)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>632<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 1000</B>
<BR/>(41 to 186)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>42 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>365 per 1000</B>
<BR/>(171 to 782)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events: retinal detachment during follow-up</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 6.13 </B>
<BR/>(2.81 to 13.38)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>790<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>25 per 1000</B>
<BR/>(11 to 54)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>36 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>221 per 1000</B>
<BR/>(101 to 482)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Wide 95% confidence interval which cannot exclude significant benefit for treated eyes</P>
<P>
<SUP>2</SUP> A subjective outcome such as quality of life is at high risk of bias when the experimental treatment is an invasive surgical procedure compared to observation.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2008-12-06 17:48:58 +0000" MODIFIED_BY="Gianni Virgili"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-02-17 17:28:15 +0000" MODIFIED_BY="Richard P L Wormald">
<COMPARISON ID="CMP-001" MODIFIED="2009-02-17 17:28:15 +0000" MODIFIED_BY="Richard P L Wormald" NO="1">
<NAME>Macular surgery versus observation</NAME>
<DICH_OUTCOME CHI2="0.18829659223764478" CI_END="1.0912795396555794" CI_START="0.8408217394240515" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9578995567026234" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="199" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.03793601271434289" LOG_CI_START="-0.07529606816219785" LOG_EFFECT_SIZE="-0.018680027723927493" METHOD="MH" MODIFIED="2009-02-17 17:28:15 +0000" MODIFIED_BY="Richard P L Wormald" NO="1" P_CHI2="0.6643381536958504" P_Q="0.0" P_Z="0.5178422689947314" Q="0.0" RANDOM="NO" SCALE="2.6875248350572507" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="366" TOTAL_2="349" WEIGHT="100.0" Z="0.6466750639163229">
<NAME>Visual loss of 2+ lines at 1 year</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours observation</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1311845730434409" CI_START="0.7574211550623227" EFFECT_SIZE="0.9256258023106547" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="82" LOG_CI_END="0.053533473638298204" LOG_CI_START="-0.12066256903493865" LOG_EFFECT_SIZE="-0.033564547698320235" MODIFIED="2008-09-06 10:17:00 +0100" MODIFIED_BY="Gianni Virgili" ORDER="9" O_E="0.0" SE="0.10232361775057727" STUDY_ID="STD-SST-2004-Group-B" TOTAL_1="152" TOTAL_2="139" VAR="0.010470122749566251" WEIGHT="42.03979478145931"/>
<DICH_DATA CI_END="1.1649306647837439" CI_START="0.8266296244334675" EFFECT_SIZE="0.9813084112149533" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="117" LOG_CI_END="0.0663000774668316" LOG_CI_START="-0.08268903469737472" LOG_EFFECT_SIZE="-0.00819447861527157" MODIFIED="2008-04-12 16:09:44 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.08751694199325437" STUDY_ID="STD-SST-2004-Group-N" TOTAL_1="214" TOTAL_2="210" VAR="0.007659215135850651" WEIGHT="57.96020521854069"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03230268614819935" CI_END="1.5017638650486291" CI_START="0.7456635541430705" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0582110286213215" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.17660165026568153" LOG_CI_START="-0.12745708343659173" LOG_EFFECT_SIZE="0.024572283414544916" METHOD="MH" MODIFIED="2008-12-02 09:39:50 +0000" MODIFIED_BY="Gianni Virgili" NO="2" P_CHI2="0.8573649936952269" P_Q="0.0" P_Z="0.7514059110091125" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="366" TOTAL_2="349" WEIGHT="100.00000000000001" Z="0.3167861019744744">
<NAME>Visual gain of 2+ lines at 1 year</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours observation</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7310240415443723" CI_START="0.6036225796522935" EFFECT_SIZE="1.022196261682243" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.23830309967062818" LOG_CI_START="-0.21923452298030804" LOG_EFFECT_SIZE="0.00953428834516006" MODIFIED="2008-09-06 10:19:44 +0100" MODIFIED_BY="Gianni Virgili" ORDER="35" O_E="0.0" SE="0.26875986439291905" STUDY_ID="STD-SST-2004-Group-B" TOTAL_1="214" TOTAL_2="210" VAR="0.07223186470850022" WEIGHT="47.144176562917956"/>
<DICH_DATA CI_END="1.7405463330010855" CI_START="0.6830201682499475" EFFECT_SIZE="1.090334008097166" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" LOG_CI_END="0.24068558860788258" LOG_CI_START="-0.1655664722623282" LOG_EFFECT_SIZE="0.03755955817277724" MODIFIED="2008-12-02 09:39:50 +0000" MODIFIED_BY="Gianni Virgili" ORDER="36" O_E="0.0" SE="0.23863447153529582" STUDY_ID="STD-SST-2004-Group-N" TOTAL_1="152" TOTAL_2="139" VAR="0.056946411004929906" WEIGHT="52.85582343708206"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6490020033805642" CI_END="1.023194634735578" CI_START="0.6278948034181665" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8015351483471068" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.009958254192605409" LOG_CI_START="-0.20211311123398118" LOG_EFFECT_SIZE="-0.09607742852068786" METHOD="MH" MODIFIED="2008-12-06 15:09:52 +0000" MODIFIED_BY="Gianni Virgili" NO="3" P_CHI2="0.420469983983749" P_Q="0.0" P_Z="0.07575013059654533" Q="0.0" RANDOM="NO" SCALE="4.35" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="355" TOTAL_2="334" WEIGHT="100.0" Z="1.7758955741052829">
<NAME>Contrast threshold loss -0.15 log units or more at 1 year</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours observation</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1458254709759912" CI_START="0.653323809646151" EFFECT_SIZE="0.8652138821630347" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="59" LOG_CI_END="0.05911847211273076" LOG_CI_START="-0.1848715141513552" LOG_EFFECT_SIZE="-0.06287652101931222" MODIFIED="2008-09-06 10:35:15 +0100" MODIFIED_BY="Gianni Virgili" ORDER="11" O_E="0.0" SE="0.14332092570143476" STUDY_ID="STD-SST-2004-Group-B" TOTAL_1="147" TOTAL_2="134" VAR="0.020540887743916186" WEIGHT="62.71069655867604"/>
<DICH_DATA CI_END="1.10622466999621" CI_START="0.4359449752837326" EFFECT_SIZE="0.6944444444444444" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="36" LOG_CI_END="0.043843339473731056" LOG_CI_START="-0.3605683236642305" LOG_EFFECT_SIZE="-0.15836249209524966" MODIFIED="2008-12-06 15:09:20 +0000" MODIFIED_BY="Gianni Virgili" ORDER="85" O_E="0.0" SE="0.2375534127972569" STUDY_ID="STD-SST-2004-Group-N" TOTAL_1="208" TOTAL_2="200" VAR="0.05643162393162394" WEIGHT="37.28930344132396"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.94931749064325" CI_END="1.196916910511931" CI_START="0.6408203102164279" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8757903093192708" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="66" I2="48.69999346950852" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.07806400290544391" LOG_CI_START="-0.19326373213739748" LOG_EFFECT_SIZE="-0.05759986461597681" METHOD="MH" MODIFIED="2008-12-06 17:13:57 +0000" MODIFIED_BY="Gianni Virgili" NO="4" P_CHI2="0.16266070393713927" P_Q="0.0" P_Z="0.4053202433614811" Q="0.0" RANDOM="NO" SCALE="5.81" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="357" TOTAL_2="335" WEIGHT="100.0" Z="0.8321571706915417">
<NAME>Reading speed 40 word/minute or more after 1 year</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours observation</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6628371369267274" CI_START="0.7108987932502325" EFFECT_SIZE="1.087248322147651" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="30" LOG_CI_END="0.22084971524616298" LOG_CI_START="-0.14819222298544923" LOG_EFFECT_SIZE="0.036328746130356894" MODIFIED="2008-12-06 15:33:55 +0000" MODIFIED_BY="Gianni Virgili" ORDER="86" O_E="0.0" SE="0.21677706130430532" STUDY_ID="STD-SST-2004-Group-B" TOTAL_1="149" TOTAL_2="135" VAR="0.04699229430773055" WEIGHT="46.16702511573652"/>
<DICH_DATA CI_END="1.10622466999621" CI_START="0.4359449752837326" EFFECT_SIZE="0.6944444444444444" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="36" LOG_CI_END="0.043843339473731056" LOG_CI_START="-0.3605683236642305" LOG_EFFECT_SIZE="-0.15836249209524966" MODIFIED="2008-12-06 15:36:21 +0000" MODIFIED_BY="Gianni Virgili" ORDER="13" O_E="0.0" SE="0.2375534127972569" STUDY_ID="STD-SST-2004-Group-N" TOTAL_1="208" TOTAL_2="200" VAR="0.05643162393162394" WEIGHT="53.83297488426347"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.11831129316991965" CI_END="1.6800803389085956" CI_START="1.089700805732138" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3530650017657764" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.2253300495297084" LOG_CI_START="0.037307272017484176" LOG_EFFECT_SIZE="0.13131866077359633" METHOD="IV" MODIFIED="2008-12-16 10:45:21 +0000" MODIFIED_BY="Anupa Shah" NO="5" P_CHI2="0.7308733486333796" P_Q="1.0" P_Z="0.006186074969552458" Q="0.0" RANDOM="NO" SCALE="4.28" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="331" TOTAL_2="358" WEIGHT="100.0" Z="2.73775176624596">
<NAME>Loss of 6+ points of overall NEI-VFQ score at 1 year</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours observation</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.869725708296694" CI_START="1.0475980926584696" EFFECT_SIZE="1.3995431703974417" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="55" LOG_CI_END="0.2717778995255131" LOG_CI_START="0.020194699042373785" LOG_EFFECT_SIZE="0.14598629928394344" MODIFIED="2008-09-06 10:47:37 +0100" MODIFIED_BY="Gianni Virgili" ORDER="9" O_E="0.0" SE="0.14778121732072333" STUDY_ID="STD-SST-2004-Group-B" TOTAL_1="199" TOTAL_2="207" VAR="0.021839288192794855" WEIGHT="55.85443364337167"/>
<DICH_DATA CI_END="1.795784915770203" CI_START="0.9359810101822832" EFFECT_SIZE="1.2964646464646465" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="45" LOG_CI_END="0.25425431925341624" LOG_CI_START="-0.028732962433591684" LOG_EFFECT_SIZE="0.11276067840991227" MODIFIED="2008-06-14 16:16:00 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.16622813007258477" STUDY_ID="STD-SST-2004-Group-N" TOTAL_1="132" TOTAL_2="151" VAR="0.027631791227428162" WEIGHT="44.14556635662833"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.053200015452089" CI_END="18.608564960275423" CI_START="4.059319351008662" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.691266181503575" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="7" I2="51.295539037885085" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="1.269712882864032" LOG_CI_START="0.6084532190741638" LOG_EFFECT_SIZE="0.9390830509690979" METHOD="MH" MODIFIED="2008-12-16 10:45:21 +0000" MODIFIED_BY="Anupa Shah" NO="6" P_CHI2="0.15188710525151172" P_Q="0.0" P_Z="2.5937523880012827E-8" Q="0.0" RANDOM="NO" SCALE="102.47" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="320" TOTAL_2="312" WEIGHT="100.0" Z="5.5668568920190795">
<NAME>Adverse events: cataract surgery at 1 year</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours observation</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.37038747030196" CI_START="4.24664426396466" EFFECT_SIZE="17.409326424870468" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="2" LOG_CI_END="1.8535180545509213" LOG_CI_START="0.6280458822132192" LOG_EFFECT_SIZE="1.2407819683820702" MODIFIED="2008-11-10 15:27:16 +0000" MODIFIED_BY="Gianni Virgili" ORDER="16" O_E="0.0" SE="0.7198484202162536" STUDY_ID="STD-SST-2004-Group-B" TOTAL_1="193" TOTAL_2="192" VAR="0.5181817480878361" WEIGHT="28.056865901352783"/>
<DICH_DATA CI_END="13.254605818607427" CI_START="2.112342258961994" EFFECT_SIZE="5.291338582677166" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="5" LOG_CI_END="1.122366816690072" LOG_CI_START="0.32476428750566483" LOG_EFFECT_SIZE="0.7235655520978684" MODIFIED="2008-11-10 15:27:30 +0000" MODIFIED_BY="Gianni Virgili" ORDER="17" O_E="0.0" SE="0.46851567383911596" STUDY_ID="STD-SST-2004-Group-N" TOTAL_1="127" TOTAL_2="120" VAR="0.2195069366329209" WEIGHT="71.94313409864722"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5653938325978001" CI_END="13.379609742630972" CI_START="2.8098455341256354" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.1314465408805034" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="1.1264434460854915" LOG_CI_START="0.44868244605428154" LOG_EFFECT_SIZE="0.7875629460698865" METHOD="MH" MODIFIED="2008-12-16 10:45:21 +0000" MODIFIED_BY="Anupa Shah" NO="7" P_CHI2="0.45209522590506945" P_Q="0.0" P_Z="5.23897464631504E-6" Q="0.0" RANDOM="NO" SCALE="197.6991154544648" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="396" TOTAL_2="394" WEIGHT="100.0" Z="4.554983275178591">
<NAME>Adverse events: retinal detachment during follow-up</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="90.72007284814302" CI_START="1.559575076397576" EFFECT_SIZE="11.894736842105264" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.957703390287079" LOG_CI_START="0.19300628610206497" LOG_EFFECT_SIZE="1.075354838194572" MODIFIED="2008-11-10 15:35:05 +0000" MODIFIED_BY="Gianni Virgili" ORDER="19" O_E="0.0" SE="1.0365918143898256" STUDY_ID="STD-SST-2004-Group-B" TOTAL_1="228" TOTAL_2="226" VAR="1.0745225896599908" WEIGHT="14.339622641509436"/>
<DICH_DATA CI_END="12.059225247729186" CI_START="2.213611894302343" EFFECT_SIZE="5.166666666666667" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" LOG_CI_END="1.0813194071868684" LOG_CI_START="0.34510147971438976" LOG_EFFECT_SIZE="0.7132104434506291" MODIFIED="2008-11-10 15:35:45 +0000" MODIFIED_BY="Gianni Virgili" ORDER="18" O_E="0.0" SE="0.43245805493485" STUDY_ID="STD-SST-2004-Group-N" TOTAL_1="168" TOTAL_2="168" VAR="0.18701996927803377" WEIGHT="85.66037735849056"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="80" EVENTS_2="179" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-12-16 10:45:21 +0000" MODIFIED_BY="Anupa Shah" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="320" TOTAL_2="312" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events: leakage of dye from CNV recurrence at 1 year</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours observation</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.431426897048725" CI_START="0.2766965007032953" EFFECT_SIZE="0.34550587943284417" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="167" LOG_CI_END="-0.3650927825628589" LOG_CI_START="-0.5579963332148814" LOG_EFFECT_SIZE="-0.46154455788887017" MODIFIED="2008-11-10 15:23:27 +0000" MODIFIED_BY="Gianni Virgili" ORDER="14" O_E="0.0" SE="0.113312500540974" STUDY_ID="STD-SST-2004-Group-B" TOTAL_1="193" TOTAL_2="192" VAR="0.012839722778848234" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.3436653325843437" CI_START="0.8974600335652189" EFFECT_SIZE="1.7322834645669292" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.5242228024136893" LOG_CI_START="-0.04698488268119056" LOG_EFFECT_SIZE="0.2386189598662494" MODIFIED="2008-11-10 15:24:05 +0000" MODIFIED_BY="Gianni Virgili" ORDER="15" O_E="0.0" SE="0.3355302217483754" STUDY_ID="STD-SST-2004-Group-N" TOTAL_1="127" TOTAL_2="120" VAR="0.11258052970651396" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-12-16 09:57:43 +0000" MODIFIED_BY="Anupa Shah" NO="2">
<NAME>Macular surgery versus laser photocoagulation</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-12 04:51:59 +0000" MODIFIED_BY="Gianni Virgili" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="25.470754107738983" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Loss 2+ lines of visual acuity at 1 year</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Photocoagulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7598267217616963" CI_START="0.5954401176350832" EFFECT_SIZE="1.0236559139784946" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.24546990787808548" LOG_CI_START="-0.225161908217007" LOG_EFFECT_SIZE="0.010153999830539237" MODIFIED="2008-11-09 14:25:27 +0000" MODIFIED_BY="Gianni Virgili" ORDER="24" O_E="0.0" SE="0.27645145843931934" STUDY_ID="STD-SST-2000" TOTAL_1="31" TOTAL_2="34" VAR="0.07642540887322671" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-12 04:52:27 +0000" MODIFIED_BY="Gianni Virgili" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.04" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Gain 2+ lines of visual acuity at 1 year</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Photocoagulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours photocoagulation</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4942533998487875" CI_START="0.3543237749771263" EFFECT_SIZE="0.9400921658986175" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3969405728657258" LOG_CI_START="-0.4505997057109872" LOG_EFFECT_SIZE="-0.02682956642263074" MODIFIED="2008-11-09 14:26:34 +0000" MODIFIED_BY="Gianni Virgili" ORDER="25" O_E="0.0" SE="0.4978493550280026" STUDY_ID="STD-SST-2000" TOTAL_1="31" TOTAL_2="34" VAR="0.24785398030179817" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-12 04:52:51 +0000" MODIFIED_BY="Gianni Virgili" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="24.66" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Loss of 5+ points of SF-36 Physical Component Score</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Photocoagulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours photocoagulation</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9478729493060642" CI_START="0.4022150997466801" EFFECT_SIZE="1.0888888888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.4695087618856808" LOG_CI_START="-0.3955416293793409" LOG_EFFECT_SIZE="0.036983566253169946" MODIFIED="2008-11-09 14:53:48 +0000" MODIFIED_BY="Gianni Virgili" ORDER="40" O_E="0.0" SE="0.5081348818975708" STUDY_ID="STD-SST-2000" TOTAL_1="27" TOTAL_2="21" VAR="0.2582010582010582" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-12 04:53:11 +0000" MODIFIED_BY="Gianni Virgili" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.88" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Loss of 5+ points of SF-36 Mental Component Score</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Photocoagulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours photocoagulation</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8352787774817423" CI_START="0.22890038674358992" EFFECT_SIZE="0.6481481481481481" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.263702042607834" LOG_CI_START="-0.6403534735532198" LOG_EFFECT_SIZE="-0.1883257154726929" MODIFIED="2008-11-09 14:55:12 +0000" MODIFIED_BY="Gianni Virgili" ORDER="41" O_E="0.0" SE="0.5310466853399822" STUDY_ID="STD-SST-2000" TOTAL_1="27" TOTAL_2="21" VAR="0.28201058201058204" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-12 04:53:31 +0000" MODIFIED_BY="Gianni Virgili" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events: cataract surgery during follow-up</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Photocoagulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours photocoagulation</GRAPH_LABEL_2>
<DICH_DATA CI_END="106.2712300357885" CI_START="0.2629006505410285" EFFECT_SIZE="5.285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.026415707347043" LOG_CI_START="-0.5802083392415666" LOG_EFFECT_SIZE="0.7231036840527382" MODIFIED="2008-11-10 15:38:30 +0000" MODIFIED_BY="Gianni Virgili" ORDER="20" O_E="0.0" SE="1.5311438679632767" STUDY_ID="STD-SST-2000" TOTAL_1="34" TOTAL_2="36" VAR="2.3444015444015442" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-12 05:03:07 +0000" MODIFIED_BY="Gianni Virgili" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events: retinal detachment during follow-up</NAME>
<GROUP_LABEL_1>Macular surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Photocoagulation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours surgery</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours photocoagulation</GRAPH_LABEL_2>
<DICH_DATA CI_END="138.15916582412086" CI_START="0.3963544486777702" EFFECT_SIZE="7.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.140379702388912" LOG_CI_START="-0.40191626292695937" LOG_EFFECT_SIZE="0.8692317197309762" MODIFIED="2008-11-10 15:39:37 +0000" MODIFIED_BY="Gianni Virgili" ORDER="21" O_E="0.0" SE="1.4933572345945325" STUDY_ID="STD-SST-2000" TOTAL_1="34" TOTAL_2="36" VAR="2.23011583011583" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-02-17 17:28:17 +0000" MODIFIED_BY="Richard P L Wormald">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-02-17 17:28:17 +0000" MODIFIED_BY="Richard P L Wormald" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Macular surgery versus observation, outcome: 1.1 Visual loss of 2+ lines at 1 year.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtkAAACgCAMAAADuIYCMAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-12-19 18:33:20 +0000" MODIFIED_BY="Gianni Virgili" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Macular surgery versus observation, outcome: 1.2 Visual gain of 2+ lines at 1 year.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtkAAACgCAMAAADuIYCMAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-12-19 18:33:20 +0000" MODIFIED_BY="Gianni Virgili" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXAAAAFECAIAAACxkPLTAAAQaklEQVR42u3dMW4cOROGYR1AgQMf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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-12-19 18:33:20 +0000" MODIFIED_BY="Gianni Virgili" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAAEZCAMAAAC0DjydAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-02-16 19:20:52 +0000" MODIFIED_BY="Anupa Shah">
<APPENDIX ID="APP-01" MODIFIED="2009-02-13 13:42:43 +0000" MODIFIED_BY=" Iris Gordon" NO="1">
<TITLE MODIFIED="2009-02-13 13:40:18 +0000" MODIFIED_BY=" Iris Gordon">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-13 13:42:43 +0000" MODIFIED_BY=" Iris Gordon">
<P>#1 MeSH descriptor Macular Degeneration<BR/>#2 MeSH descriptor Retinal Degeneration<BR/>#3 MeSH descriptor Retinal Neovascularization<BR/>#4 MeSH descriptor Choroidal Neovascularization<BR/>#5 MeSH descriptor Macula Lutea<BR/>#6 macula* near lutea*<BR/>#7 ((macul* OR retina* OR choroid*:TI) AND (degener* OR neovasc*:TI))<BR/>#8 ((macul* OR retina* OR choroid*:AB) AND (degener* OR neovasc*:AB))<BR/>#9 maculopath*<BR/>#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)<BR/>#11 (surg* or excis* or remov* or resect*) near (submacul*)<BR/>#12 #10 and #11</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-02-13 13:43:39 +0000" MODIFIED_BY=" Iris Gordon" NO="2">
<TITLE MODIFIED="2009-02-13 13:40:34 +0000" MODIFIED_BY=" Iris Gordon">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-13 13:43:39 +0000" MODIFIED_BY=" Iris Gordon">
<P>1. randomized controlled trial. pt.<BR/>2. (randomised or randomised).ab,ti.<BR/>3. placebo.ab,ti.<BR/>4. dt.fs.<BR/>5. randomly.ab,ti.<BR/>6. trial.ab,ti.<BR/>7. groups.ab,ti.<BR/>8. or/1-7<BR/>9. exp animals/<BR/>10. exp humans/<BR/>11. 9 not (9 and 10)<BR/>12. 8 not 11<BR/>13. exp macular degeneration/<BR/>14. exp retinal degeneration/<BR/>15. exp retinal neovascularization/<BR/>16. exp choroidal neovascularization/<BR/>17. exp macula lutea/<BR/>18. maculopath$.tw.<BR/>19. ((macul$ or retina$ or choroid$) adj3 degener$).tw.<BR/>20. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.<BR/>21. (macula$ adj2 lutea).tw.<BR/>22. or/13-21<BR/>23. ((surg$ or excis$ or remov$ or resect$) adj4 submacula$).tw.<BR/>24. 22 and 23<BR/>25. 12 and 24</P>
<P>The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (<LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-02-13 13:44:32 +0000" MODIFIED_BY=" Iris Gordon" NO="3">
<TITLE MODIFIED="2009-02-13 13:40:59 +0000" MODIFIED_BY=" Iris Gordon">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-13 13:44:32 +0000" MODIFIED_BY=" Iris Gordon">
<P>1. exp randomized controlled trial/<BR/>2. exp randomization/<BR/>3. exp double blind procedure/<BR/>4. exp single blind procedure/<BR/>5. random$.tw.<BR/>6. or/1-5<BR/>7. (animal or animal experiment).sh.<BR/>8. human.sh.<BR/>9. 7 and 8<BR/>10. 7 not 9<BR/>11. 6 not 10<BR/>12. exp clinical trial/<BR/>13. (clin$ adj3 trial$).tw.<BR/>14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.<BR/>15. exp placebo/<BR/>16. placebo$.tw.<BR/>17. random$.tw.<BR/>18. exp experimental design/<BR/>19. exp crossover procedure/<BR/>20. exp control group/<BR/>21. exp latin square design/<BR/>22. or/12-21<BR/>23. 22 not 10<BR/>24. 23 not 11<BR/>25. exp comparative study/<BR/>26. exp evaluation/<BR/>27. exp prospective study/<BR/>28. (control$ or prospectiv$ or volunteer$).tw.<BR/>29. or/25-28<BR/>30. 29 not 10<BR/>31. 30 not (11 or 23)<BR/>32. 11 or 24 or 31<BR/>33. exp retina macula degeneration/<BR/>34. exp retina degeneration/<BR/>35. exp retina neovascularization/<BR/>36. exp subretinal neovascularization/<BR/>37. maculopath$.tw.<BR/>38. ((macul$ or retina$ or choroid$) adj3 degener$).tw.<BR/>39. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.<BR/>40. exp retina macula lutea/<BR/>41. (macula$ adj2 lutea$).tw.<BR/>42. or/33-40<BR/>43. ((surg$ or excis$ or remov$ or resect$) adj4 submacula$).tw.<BR/>44. 42 and 43<BR/>45. 32 and 44</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-02-16 19:20:52 +0000" MODIFIED_BY="Anupa Shah" NO="4">
<TITLE MODIFIED="2009-02-13 13:46:28 +0000" MODIFIED_BY=" Iris Gordon">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-16 19:20:52 +0000" MODIFIED_BY="Anupa Shah">
<P>macul$ or retina$ or choroid$ and degenerat$ or neovascula$ and submacula$</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>